Glycoengineering of E-selectin ligands

By using modRNA to intracellularly express fucosyltransferases, MSCs are engineered to produce E-selectin and L-selectin ligands, addressing the homing challenge and improving their therapeutic effectiveness in bone marrow targeting.

JP7595700B2Active Publication Date: 2024-12-06SACHSTEIN ROBERT
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023079280
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-06-24
Filing Date
2023-05-12
Publication Date
2024-12-06
Estimated Expiration
2037-05-22

AI Technical Summary

Technical Problem

Existing methods for optimizing the osteotropism of intravascularly administered mesenchymal stem cells (MSCs) are inadequate due to the lack of E-selectin ligands, limiting their homing to bone marrow, which is crucial for treating conditions like osteoporosis and osteogenesis imperfecta.

Method used

Introduce synthetically modified mRNA (modRNA) to intracellularly express alpha-(1,3)-fucosyltransferase enzymes, allowing MSCs to produce E-selectin and L-selectin ligands, enhancing their homing and extravasation to therapeutic sites by modifying glycan chains on cellular glycoproteins.

Benefits of technology

The modRNA approach provides transient yet effective expression of E-selectin ligands, improving MSC homing and extravasation to bone marrow, potentially enhancing the therapeutic efficacy of MSCs in treating bone-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595700000026
    Figure 0007595700000026
  • Figure 0007595700000027
    Figure 0007595700000027
  • Figure 0007595700000028
    Figure 0007595700000028
Patent Text Reader

Abstract

To provide glycoengineering of E-selectin ligands.SOLUTION: The invention provides a method for enforcing expression of an E-selectin and / or L-selectin ligand on a surface of a cell. The invention also provides a method for enabling and / or increasing binding of a cell to E-selectin and / or L-selectin, a method for increasing homing and / or extravasation in a population of transplanted cells, a method for producing modified cells including stem cells for transplantation to a subject, a method for treating or ameliorating the effects of a symptom, a disease or an injury in a subject, and a method for inducing and / or enhancing homing of a cell population to a therapeutic target in a subject. Further the invention provides a pharmaceutical composition comprising a cell population prepared by the method of the invention, and a kit comprising such a composition for treating or ameliorating the effects of a symptom, a disease or an injury in a subject.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 339,704, filed May 20, 2016, and U.S. Provisional Patent Application No. 62 / 354,350, filed June 24, 2016, the entire contents of which are incorporated by reference as if fully set forth herein. [Background technology]

[0002] Background of the Invention Mesenchymal stem cells (MSCs) hold great promise for cell therapy due to their easy isolation and in vitro expansion, multilineage differentiation potential, tissue repair trophic activity, and potent immunomodulatory capabilities [Dominici, 2006; Griffin, 2013]. In particular, because MSCs are precursors of bone-forming osteoblasts, these cells have attracted considerable interest for the treatment of systemic bone diseases such as osteoporosis or osteogenesis imperfecta. However, to achieve this goal, it is first necessary to optimize the osteotropism of intravascularly administered MSCs.

[0003] Recruitment of circulating cells to bone depends on E-selectin receptor / ligand adhesive interactions. E-selectin is a calcium-dependent lectin that is constitutively expressed on bone marrow microvessels and inducibly expressed on microvessels at sites of inflammation [Sipkins, 2005; Schweitzer, 1996; Sackstein, 2009]. E-selectin is a sialyl Lewis X (sLe X sLe primarily binds to a sialofucosylated terminal tetrasaccharide motif known as NeuAc-α(2,3)-Gal-β(1,4)-[Fuc-α(1,3)]GlcNAc-R). X sLe can be presented at the terminus of glycan chains that decorate specific cell surface glycoproteins, such as PSGL-1, CD43, or CD44. XWhen presented on these proteins, they can function as E-selectin ligands CLA, CD43E, or HCELL, respectively [Dimitroff, 2001; Sackstein, 2008]. These structures are expressed at high levels on hematopoietic stem and progenitor cells (HSPCs) and other hematopoietic cells, but are completely absent on MSCs. Partly due to the lack of this E-selectin ligand, only a small proportion of MSCs injected intravenously home to bone [Schrepfer, 2007; Lee, 2009; Ankrum, 2010].

[0004] The glycan modifications required to generate E-selectin ligands are carried out in the Golgi by specific glycosyltransferases that act in a stepwise manner. Human MSCs express CD44 and sLe XMSCs express high levels of glycosyltransferases required for the synthesis of α-(1,3)-fucosylation, with the notable exception of a complete lack of expression of any of the fucosyltransferases mediating α-(1,3)-fucosylation: FTIII, FTIV, FTV, FTVI, or FTVII [Sackstein, 2009]. Thus, MSCs express CD44 on their cell surface decorated with terminal sialylated lactosamine (NeuAc-α(2,3)-Gal-β(1,4)-GlcNAc-R), which requires only the addition of α-(1,3)-fucose to be converted into the potent E-selectin ligand HCELL. Previously, we developed a method to modify the surface glycans of MSCs to generate E-selectin ligands by incubating intact cells with purified α-(1,3)-fucosyltransferase enzyme FTVI and its nucleotide sugar donor, GDP-fucose. This method, termed "glycosyl transferase-mediated stereosubstitution" (GPS), results in the transient production of E-selectin ligands (primarily HCELL) on the MSC cell surface. FTVI-driven exofucosylation of such MSCs has been demonstrated to robustly enhance E-selectin-mediated tethering and rolling on endothelial cells, resulting in MSC osteotropism (i.e., homing to bone) in preclinical studies [Sackstein, 2008]. Based in part on these results, the efficacy of this approach is currently being investigated in a clinical trial using exofucosylated MSCs for the treatment of osteoporosis [NCT02566655, clinicaltrials.gov]. Summary of the Invention [Means for solving the problem]

[0005] Summary of the Invention Despite the promise of these methods, there is a continuing need for improved methods to engineer cell surface proteins, such as E-selectin ligands, that provide the robust modification, homing, and engraftment required for cell therapy. In part, the present invention provides an alternative approach in which fucosyltransferase enzymes can be produced intracellularly by introducing synthetically modified mRNA (modRNA) [Levy, 2013; Warren, 2010]. Similar to exofucosylation, the resulting effect is transient, allowing MSCs to return to their native state after homing. However, the modRNA approach is distinct because it utilizes the MSCs' own cellular machinery to access intracellular stores of GDP-fucose to produce the fucosyltransferase enzyme. Furthermore, while endogenous FTVI is membrane-bound and tethered to the Golgi membrane, the purified FTVI used for exofucosylation is soluble and consists only of the stem and catalytic domain of the protein. The modRNA approach leaves open biological questions, particularly because Golgi localization provides the enzyme with access to acceptors distinct from those accessible to cell surface fucosylation. As such, it is unclear whether E-selectin ligands generated by exofucosylation are similar in identity and functionality to those generated by the action of intracellular fucosyltransferases. Furthermore, the kinetics of newly synthesized E-selectin ligand presentation (and subsequent disappearance) on the MSC surface appear to differ from those of exofucosylated MSCs. Most importantly, it is unclear whether such differences lead to differences in the ability of these cells to home to the bone marrow and to mediate E-selectin ligand-mediated functions.

[0006] To address these issues, we performed a direct comparison of intracellular and extracellular fucosylation using the same alpha-(1,3)-fucosyltransferase in human cells that naturally lack such enzymes. To this end, we used multiple primary human MSC cultures to transiently produce FTVI protein in human MSCs using modRNA and compared the biochemical and functional properties of the resulting E-selectin ligand with that produced via FTVI exofucosylation. Furthermore, we directly compared the in vivo homing properties of both types of treated cells by performing in vivo imaging of MSCs transplanted into mouse calvaria. This detailed comparison of FTVI-mediated intracellular versus extracellular fucosylation provides important information about the activity and function of fucosyltransferase VI in programming cell migration and offers important insights into the most appropriate fucosylation approach for clinical utility.

[0007] Accordingly, the present invention provides a method for forcing expression of an E-selectin and / or L-selectin ligand on the surface of a cell, comprising providing the cell with a nucleic acid encoding a glycosyltransferase and culturing the cell under conditions sufficient to express the glycosyltransferase, wherein the expressed glycosyltransferase modifies terminal sialylated lactosamines present on glycoproteins of the cell to force expression of the E-selectin and / or L-selectin ligand.

[0008] The present invention also provides a method for enabling and / or increasing binding of a cell to E-selectin and / or L-selectin, comprising providing a cell with a nucleic acid encoding an alpha 1,3-fucosyltransferase and culturing the cell under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by the cell, wherein the alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to generate E-selectin and / or L-selectin ligands, thereby enabling and / or increasing binding of the cell to E-selectin and / or L-selectin.

[0009] In another embodiment, the invention provides a method for increasing homing and / or extravasation in a population of cells transplanted into a subject, comprising the steps of providing a population of cells with a nucleic acid encoding an alpha 1,3-fucosyltransferase; culturing the population of cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the alpha 1,3-fucosyltransferase fucosylates glycan chains present on glycoproteins to generate modified cells having enforced E-selectin and / or L-selectin ligand expression; and transplanting the population of cells into the subject, wherein the modified cells with enforced E-selectin and / or L-selectin ligand expression exhibit increased homing and / or extravasation to therapeutically useful sites.

[0010] The present invention also provides a method for producing modified cells for transplantation into a subject in need thereof, comprising the steps of obtaining a population of cells to be modified, providing the population of cells with a nucleic acid encoding an alpha 1,3-fucosyltransferase, and culturing the population of cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to produce E-selectin and / or L-selectin ligands.

[0011] The present invention also provides a method for producing modified stem cells for transplantation into a subject, comprising the steps of obtaining a population of stem cells to be modified, providing the population of stem cells with cDNA or modified RNA encoding an alpha 1,3-fucosyltransferase, and culturing the population of stem cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the expressed alpha 1,3-fucosyltransferase fucosylates CD44 present on or in the one or more modified cells.

[0012] The present invention also provides a method of treating or ameliorating the effects of a condition, disease, or injury in a subject in need thereof, comprising obtaining a population of cells produced by any of the methods of the present invention and transplanting an effective amount of the population of cells into the subject, wherein the transplanted cells extravasate to sites expressing E-selectin and / or L-selectin, thereby treating or ameliorating the effects of the condition, disease, or injury in the subject.

[0013] The present invention also provides a pharmaceutical composition comprising a population of cells produced by the method of the present invention and a pharmaceutically acceptable carrier.

[0014] The present invention also provides kits for treating or ameliorating the effects of a condition, disease or injury in a subject in need thereof, comprising a composition of the present invention packaged together with instructions for its use.

[0015] The present invention also provides a method for inducing and / or enhancing homing of a population of cells to a therapeutic target in a subject in need thereof, comprising the steps of: (a) providing to the population of cells a nucleic acid encoding a polypeptide that forces transient expression of a ligand that binds to a receptor at the therapeutic target; and (b) causing the population of cells to express the polypeptide, wherein upon expression of the polypeptide, homing of one or more cells in the population to the therapeutic target is induced and / or enhanced. [Brief explanation of the drawings]

[0016] [Figure 1] Figures 1A-1C show the characterization of MSCs. Figure 1A shows flow cytometry histograms of cell surface markers measured for a representative primary MSC line. Figure 1B shows the mean fluorescence intensity levels for the same markers as in panel A, presented for all seven primary MSC lines tested. Each MSC line was isolated from a different healthy donor. Figure 1C shows photomicrographs of MSCs subjected to osteogenic differentiation conditions (lower left panel), adipogenic differentiation conditions (lower right panel), or MSC maintenance medium (upper panel). Cells were stained with Alizarin Red to detect mineralized deposits or Oil Red O to detect lipid deposits (scale bar = 100 µm).

[0017] [Figure 2] Figure 2 shows the kinetics of sLeX surface expression after intracellular or extracellular fucosylation of MSCs. Untreated, extracellularly fucosylated (FTVI-exo) MSCs, or intracellularly fucosylated (FUT6-mod) MSCs were collected at 24-h intervals, stained for sLeX using the HECA452 antibody, and analyzed by flow cytometry. MFI: mean fluorescence intensity.

[0018] [Figure 3] Figures 3A-B show cell surface sLeX expression levels induced by intracellular or extracellular fucosylation in multiple primary human MSC lines. Figure 3A shows that extracellularly fucosylated (FTVI-exo) MSCs on day 0 and intracellularly fucosylated (FUT6-mod) MSCs on days 2-3 exhibit a similar increase in surface sLeX compared to untreated MSCs, as measured via flow cytometry analysis of HECA452 or csLex1 staining. Figure 3B shows a similar increase in surface sLeX observed across multiple independent primary MSC lines (n = 11 experiments, each color represents one of the five primary MSC lines used). Statistical comparisons were performed using Student's t-test. ns = not significant (i.e., p > 0.05). **** indicates p < 0.0001.

[0019] [Figure 4]Figures 4A-4D show the evaluation of MSC characteristics before and after intracellular or extracellular fucosylation. Figure 4A shows the viability (%) of fucosylated MSCs measured by trypan blue exclusion. Error bars = SEM. Figure 4B shows cell surface marker expression for primary MSC lines before and after extracellular (FTVI-exo) or intracellular (FUT6-mod) fucosylation. Figure 4C shows the mean (bars) and range (error bars) of mean fluorescence intensity for a panel of positive and negative markers for two primary MSC lines measured immediately after fucosylation (left panel) or when replated and subsequently cultured for one further passage (i.e., an additional 5-11 days) (right panel). Figure 4D shows one primary MSC line treated with FTVI exofucosylation or buffer only, transfected with FUT6-mod RNA or control mod RNA, or left untreated, then plated in triplicate and induced to undergo osteogenic differentiation. Alizarin red staining measurements were performed to assess the overall amount of calcified deposits formed in each culture. Statistical comparisons were performed using one-way analysis of variance with Tukey's HSD test. ns = not significant (i.e., p > 0.05); ** = p < 0.01.

[0020] [Figure 5] Figures 5A-5B show a comparison of the protein size and cellular localization of E-selectin ligand glycoproteins generated by intracellular or extracellular fucosylation. Figure 5A shows that untreated MSCs, intracellularly fucosylated (FUT6-mod) MSCs, and extracellularly fucosylated (FTVI-exo) MSCs were lysed and Western blotted using a mouse E-selectin-human Fc (E-Ig) chimera as a probe. Figure 5B shows the cellular localization of E-Ig-reactive glycoproteins determined by treating intracellularly or extracellularly fucosylated intact MSCs with or without neuraminidase (NAse) prior to cell lysis and E-Ig Western blot. β-actin staining of the same blot was performed as a loading control.

[0021] [Figure 6] Figures 6A-6B show that the approximately 85 kD E-selectin ligand in fucosylated MSCs is HCELL, the E-selectin-binding CD44 glycoform. Figure 6A shows that E-selectin ligand from untreated, intracellularly fucosylated (FUT6-mod), and extracellularly fucosylated (FTVI-exo) MSC lysates was pulled down using an E-Ig chimera and Western blotted with a CD44 antibody. Figure 6B shows that CD44 was immunoprecipitated from untreated, intracellularly fucosylated (FUT6-mod), and extracellularly fucosylated (FTVI-exo) MSC lysates and Western blotted with mAb HECA452, which recognizes sLeX.

[0022] [Figure 7] Figure 7 shows the analysis of E-selectin ligand glycoproteins accessible to cell surface biotinylation. Untreated or intracellularly fucosylated (FUT6-mod) MSCs were incubated in flasks with an amine-reactive biotinylation reagent, and then a portion of the untreated MSCs was extracellularly fucosylated (FTVI-exo). Untreated, FUT6-mod, and FTVI-exo cell lysates were separated into pull-down (biotinylated) and supernatant (non-biotinylated) fractions. Western blots were performed using E-selectin-Ig chimera and β-actin as a loading control.

[0023] [Figure 8]Figures 8A-8B show analysis of E-selectin ligand-mediated MSC-endothelial cell interactions under shear conditions using a parallel-plate flow chamber. (A) Both extracellular fucosylation (FTVI-exo) and intracellular fucosylation (FUT6-mod) enabled MSC capture / tethering / rolling on TNFα-activated human umbilical vein endothelial cells (HUVECs) under flow conditions, but not on HUVECs pretreated with anti-E-selectin function-blocking mAb. Error bars = SEM. n = 4 independent experiments using two different primary MSC lines. (B) Extracellularly fucosylated and intracellularly fucosylated MSCs exhibit similar rolling velocities on TNFα-stimulated HUVECs. Error bars = SEM, n = 15–155 cells analyzed per time point. Statistical comparisons were performed using Student's t-test. ns = not significant.

[0024] [Figure 9] Figure 9 shows the efficacy of fucosylation confirmed in aliquots of DiD- and DiI-labeled MSC mixtures during xenotransplantation. FTVI-exofucosylated (FTVI-exo) and buffer control MSCs, or FUT6-mod RNA (FUT6-mod) and ndGFP control mod RNA-transfected MSCs, were labeled with DiI (blue) or DiD (green), mixed at a 1:1 ratio, and injected into mice. Aliquots of each injected cell mixture were stained with sLeX-conjugated mAb HECA452 (red) and imaged on glass slides to confirm the efficacy of FUT6-mod or FTVI-exo treatment and obtain accurate initiation rates. Scale bar = 100 μm.

[0025] [Figure 10]Figures 10A-10C show in vivo imaging of calvarial bone marrow to measure the relative osteotropism of xenotransplanted human MSCs. Figure 10A shows a three-dimensional reconstruction of a mouse calvarial region after transplantation of DiD- (green) and DiI- (blue)-stained MSCs. A section of bone was digitally removed to facilitate visualization of the bone marrow. Scale bar = 100 μm. Figure 10B shows that fucosylated human MSCs exhibit increased osteotropism compared to control cells 2 hours after transplantation. Figure 10C shows data from 24 hours after transplantation, demonstrating that intracellular fucosylation (FUT6-mod) results in stronger enhancement than extracellular fucosylation (FTVI-exo). Error bars = standard deviation. n = 4 mouse pairs per comparison. Statistical comparisons were performed using one-way ANOVA with Tukey's HSD test. * = p < 0.05; ** = p < 0.01.

[0026] [Figure 11] Figures 11A-11B show in vivo imaging of blood vessels to measure extravasation of xenotransplanted human MSCs into the bone marrow parenchyma. Figure 11A shows a 2D merged image stack of a calvarial region after Angiosense injection to visualize blood vessels (red) and homed DiI (blue)- and DiD (green)-stained MSCs. Scale bar = 100 μm. Figure 11B shows that intracellularly fucosylated (FUT6-mod) MSCs exhibit significantly greater MSC extravasation into the bone marrow parenchyma than extracellularly fucosylated (FTVI-exo) MSCs when compared to control cells (baseline) 24 hours after transplantation. Error bars = standard deviation. n = 4 mouse pairs per comparison. Statistical comparisons were performed using one-way ANOVA with Tukey's HSD test. ** = p < 0.01. DETAILED DESCRIPTION OF THE INVENTION

[0027] Detailed Description of the Invention In some embodiments, the invention provides methods for forcing expression of an E-selectin and / or L-selectin ligand on the surface of a cell, comprising providing the cell with a nucleic acid encoding a glycosyltransferase and culturing the cell under conditions sufficient to express the glycosyltransferase, wherein the expressed glycosyltransferase modifies terminal sialylated lactosamines present on glycoproteins of the cell to force expression of the E-selectin and / or L-selectin ligand.

[0028] Glycosyltransferases are enzymes that catalyze the formation of glycosidic linkages to form glycosides. These enzymes utilize "activated" sugar phosphates as glycosyl donors and catalyze the transfer of glycosyl groups to nucleophilic groups. The product of glycosyl transfer can be an O-, N-, S-, or C-glycoside; glycosides can be part of monosaccharides, oligosaccharides, or polysaccharides. Glycosyltransferases have been classified into over 90 families. In some embodiments, the glycosyltransferase is an alpha 1,3-fucosyltransferase. Non-limiting examples of glycosyltransferases can be found, for example, in C. Breton et al., "Structures and mechanisms of glycosyltransferases," Glycobiology, 2006, Vol. 16(2):29R-37R; D. Liang et al., "Glycosyltransferases: mechanisms and applications in natural product development," Chem. Soc. Rev., 2015, Vol. 44, pp. 8350-8374; and Taniguchi et al., "Handbook of Glycosyltransferases and Related Genes," Springer Science & Business Media, 2011. In some embodiments, the cell contains nucleic acids encoding two or more glycosyltransferases. For example, nucleic acids encoding two glycosyltransferases can simultaneously or sequentially add sugars suitable for linkage to an elongating core glycan structure, respectively. In some embodiments, the glycosyltransferase directs N-linked glycosylation. In other embodiments, the glycosyltransferase directs O-linked glycosylation. In some embodiments, the alpha 1,3-fucosyltransferase is an alpha 1,3-fucosyltransferase FTIII, FTIV, FTV, FTVI, FTVII, and combinations thereof.

[0029] In some embodiments, a glycosyltransferase modifies the terminal sialylated lactosamine intracellularly.

[0030] In some embodiments, the invention provides methods for enabling and / or increasing binding of cells to E-selectin and / or L-selectin, comprising providing a cell with a nucleic acid encoding an alpha 1,3-fucosyltransferase and culturing the cell under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by the cell, wherein the alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to generate E-selectin and / or L-selectin ligands, thereby enabling and / or increasing binding of cells to E-selectin and / or L-selectin.

[0031] As used herein, "nucleic acid" or "oligonucleotide" or "polynucleotide" refers to at least two nucleotides covalently linked together. Many variants of nucleic acids can be used for the same purpose as a given nucleic acid. Thus, nucleic acids also encompass substantially identical nucleic acids and their complements.

[0032] Nucleic acids may be single-stranded or double-stranded, or may contain portions of both double-stranded and single-stranded sequences. Nucleic acids may include DNA (both genomic and cDNA), RNA, or hybrids, and may contain combinations of deoxy- and ribonucleotides, including combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, and isoguanine. Nucleic acids may be synthesized as single-stranded molecules or expressed in cells (in vitro or in vivo) using synthetic genes. Nucleic acids may be obtained by chemical synthesis or recombinant methods.

[0033] Nucleic acids generally contain phosphodiester bonds, but may also include nucleic acid analogs that may have at least one different linkage, such as phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphosphoramidite linkages, and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with cationic, nonionic, and non-ribose backbones, including those disclosed in U.S. Patent Nos. 5,235,033 and 5,034,506. Nucleic acids containing one or more non-natural or modified nucleotides are also included within the definition of nucleic acid. Modified nucleotide analogs may be located, for example, at the 5' and / or 3' ends of the nucleic acid molecule. Representative examples of nucleotide analogs may be selected from sugar- or backbone-modified ribonucleotides. However, it should be noted that ribonucleotides containing modified nucleobases, i.e., non-natural nucleobases instead of natural nucleobases, such as uridine or cytidine modified at the 5-position, e.g., 5-(2-amino)propyluridine, 5-bromouridine; adenosine and guanosine modified at the 8-position, e.g., 8-bromoguanosine; deazanucleotides, e.g., 7-deaza-adenosine; O- and N-alkylated nucleotides, e.g., N6-methyladenosine, are also suitable. The 2'-OH group may be replaced by a group selected from H, OR, R, halo, SH, SR, NH2, NHR, NR2, or CN, where R is C1-C6 alkyl, alkenyl, or alkynyl, and halo is F, Cl, Br, or I. Modified nucleotides also include nucleotides conjugated to cholesterol via a hydroxyprolinol linkage, as disclosed, for example, in Krutzfeldt et al., Nature (October 30, 2005), Soutschek et al., Nature 432:173-178 (2004), and U.S. Patent Application Publication No. 20050107325. Modified nucleotides and nucleic acids may include locked nucleic acids (LNAs), as disclosed in U.S. Patent Application Publication No. 20020115080.Further modified nucleotides and nucleic acids are disclosed in U.S. Patent Application Publication No. 20050182005. Modifications of the ribose-phosphate backbone may be made for a variety of reasons, such as to increase the stability and half-life of such molecules in physiological environments, to enhance diffusion across cell membranes, etc. Mixtures of natural nucleic acids and analogs may be made; alternatively, mixtures of different nucleic acid analogs and mixtures of natural nucleic acids and analogs may be made.

[0034] In some embodiments, the cell is a mammalian cell. In some preferred aspects of these embodiments, the cell is a human cell.

[0035] In other embodiments, the cells are stem cells. In some preferred aspects of these embodiments, the stem cells are selected from the group consisting of embryonic stem cells, adult stem cells, hematopoietic stem cells, and induced pluripotent stem cells (iPSCs). In some preferred aspects of these embodiments, the adult stem cells are mesenchymal stem cells.

[0036] As used herein, "providing a nucleic acid to a cell" and similar grammatical forms are intended to encompass any conventional and discovered method of introducing a nucleotide sequence into a cell and expressing it. Expression may be long-term or transient, inducible, or otherwise controlled using conventional methods known to those of skill in the art. In some embodiments, the nucleic acid is provided to the cell by transfection. In other embodiments, the nucleic acid is provided to the cell by transduction.

[0037] As used herein, "transfection" is a chemically mediated method of introducing nucleic acid into a target cell. Non-limiting examples of transfection include lipid-based transfection and calcium phosphate-based transfection. As used herein, "transduction" is a virally mediated method of introducing nucleic acid into a target cell. Methods of transfection and transduction are known to those skilled in the art and can be selected to achieve effective delivery of nucleic acid based on factors known to those skilled in the art, such as cell type.

[0038] In some embodiments, the nucleic acid is selected from the group consisting of DNA, RNA, DNA / RNA hybrids, cDNA, mRNA, modified forms thereof, and combinations thereof. In preferred embodiments, the nucleic acid is modified RNA, and in more preferred embodiments, the modified RNA is modRNA.

[0039] As used herein, "modified RNA" includes base substitutions, backbone modifications, modifications to the 5' or 3' termini, and combinations thereof.

[0040] As used herein, "modRNA" refers to modified RNA in which cytidine and uridine are replaced with 5-methylcytidine and pseudouridine, respectively. Non-limiting examples of modRNA and methods for making them are provided in Example 1.

[0041] In some embodiments, the alpha 1,3-fucosyltransferase is a human alpha 1,3-fucosyltransferase. In preferred embodiments, the alpha 1,3-fucosyltransferase is human FTVI.

[0042] In some embodiments, the alpha 1,3-fucosyltransferase fucosylates a glycoprotein selected from the group consisting of PSGL-1, CD43, CD44, and combinations thereof.

[0043] In another embodiment, the invention provides a method for increasing homing and / or extravasation in a population of cells transplanted into a subject, comprising the steps of providing a population of cells with a nucleic acid encoding an alpha 1,3-fucosyltransferase; culturing the population of cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the alpha 1,3-fucosyltransferase fucosylates glycan chains present on glycoproteins to generate modified cells having enforced E-selectin and / or L-selectin ligand expression; and transplanting the population of cells into the subject, wherein the modified cells with enforced E-selectin and / or L-selectin ligand expression exhibit increased homing and / or extravasation to therapeutically useful sites.

[0044] As used herein, "enforcing expression of an E-selectin and / or L-selectin ligand" means modifying the glycan chains of a glycoprotein, e.g., by fucosylation, so that it can function as a ligand for E-selectin and / or L-selectin. Enforcing expression of an E-selectin and / or L-selectin ligand can be accomplished, for example, by providing a glycosyltransferase, e.g., alpha 1,3-fucosyltransferase, that is capable of fucosylating the glycan chains of a glycoprotein present in or on a cell.

[0045] As used herein, a "subject" is a mammal, preferably a human. In addition to humans, categories of mammals within the scope of the present invention include, for example, agricultural animals, domestic animals, laboratory animals, etc. Some examples of agricultural animals include cows, pigs, horses, goats, etc. Some examples of domestic animals include dogs, cats, etc. Some examples of laboratory animals include primates, rats, mice, rabbits, guinea pigs, etc.

[0046] In some embodiments, the population of cells is a population of mammalian cells. In some preferred aspects of these embodiments, the population of cells is a population of human cells.

[0047] In some embodiments, the population of cells is a population of stem cells. In some preferred aspects of these embodiments, the population of stem cells is selected from the group consisting of embryonic stem cells, adult stem cells, hematopoietic stem cells, and induced pluripotent stem cells (iPSCs). In some preferred aspects of these embodiments, the adult stem cells are mesenchymal stem cells.

[0048] "Transplantation" in the present invention includes all conventional and discovered methods of providing a therapeutic composition, e.g., a population of cells, to an individual. Transplantation may be a transplant of the subject's own cells or a transplant from a non-autologous donor. In some embodiments, the transplanting step is performed intravenously. In other embodiments, the transplanting step is performed at a desired extravasation site.

[0049] In another embodiment, the present invention provides a method for producing modified cells for transplantation into a subject in need thereof, comprising the steps of obtaining a population of cells to be modified, providing the population of cells with a nucleic acid encoding an alpha 1,3-fucosyltransferase, and culturing the population of cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to produce E-selectin and / or L-selectin ligands.

[0050] The present invention also provides a method for producing modified stem cells for transplantation into a subject, comprising the steps of obtaining a population of stem cells to be modified, providing the population of stem cells with cDNA or modified RNA encoding an alpha 1,3-fucosyltransferase, and culturing the population of stem cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the expressed alpha 1,3-fucosyltransferase fucosylates CD44 present on or in the one or more modified cells.

[0051] In some further embodiments, the methods of the invention further comprise the step of performing extracellular fucosylation of CD44 expressed on the surface of stem cells. As used herein, "extracellular fucosylation" refers to providing a cell, e.g., a stem cell, with an exogenous fucosyltransferase, such as FTIII, FTIV, FTV, FTVI, FTVII, or a combination thereof, as disclosed, for example, in Sackstein et al., "Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone," Nature Medicine, 2008;14:181-187 and Sackstein et al., "Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration," Immunol Rev., 2009;230:51-74.

[0052] The present invention also provides a method of treating or ameliorating the effects of a condition, disease, or injury in a subject in need thereof, comprising obtaining a population of cells produced by any of the methods of the present invention and transplanting an effective amount of the population of cells into the subject, wherein the transplanted cells extravasate to sites expressing E-selectin and / or L-selectin, thereby treating or ameliorating the effects of the condition, disease, or injury in the subject.

[0053] As used herein, the terms "treat," "treating," "treatment," and grammatical variations thereof refer to administering to an individual subject a protocol, regimen, process, or therapy that is desirable to achieve a physiological response or outcome in the subject, e.g., patient. In particular, the methods and compositions of the present invention can be used to delay the development of disease symptoms, or delay the onset of a disease or condition, or to stop the progression of disease development. However, treatment does not require that the desired physiological response or outcome be achieved in each and every subject or subject population, e.g., patient population, since every subject treated may not respond to a particular treatment protocol, regimen, process, or therapy. Thus, a given subject or subject population, e.g., patient population, may not respond or respond poorly to treatment.

[0054] As used herein, the terms "ameliorate," "ameliorating," and grammatical variations thereof mean to reduce the severity of symptoms of a disease in a subject.

[0055] In the present invention, an "effective amount" or "therapeutically effective amount" of an agent of the present invention (including a pharmaceutical composition containing an agent of the present invention) disclosed herein is an amount sufficient to effect the beneficial or desired results described herein when such agent or composition is administered to a subject. Effective dosage forms, modes of administration, and dosage amounts can be determined empirically, and making such determinations is within the skill of the art. It will be understood by those skilled in the art that dosage amounts may vary depending on the route of administration, the duration of treatment, the identity of any other agents administered, the age, size, and species of the mammal, e.g., human patient, and similar factors well known in the medical and veterinary arts. Generally, an appropriate amount of an agent or composition according to the present invention is the amount of the agent or composition that is the lowest amount effective to produce the desired effect. An effective amount of an agent or composition of the present invention can be administered in two, three, four, five, six, or more small doses administered separately at appropriate intervals.

[0056] In some embodiments, the disease is selected from the group consisting of an inflammatory disorder, an autoimmune disease, a degenerative disease, a cardiovascular disease, an ischemic disease, a cancer, a genetic disease, a metabolic disorder, and an idiopathic disorder.

[0057] In some embodiments, the injury is selected from the group consisting of a physical injury, a drug side effect, a toxic injury, and an iatrogenic condition.

[0058] In some embodiments, the subject is a mammal. In some preferred embodiments, the mammal is selected from the group consisting of humans, primates, agricultural animals, and domestic animals. In some more preferred embodiments, the mammal is a human.

[0059] In some embodiments, the transplantation is performed intravenously. In other embodiments, the transplantation is performed near the desired extravasation site. In some preferred embodiments, the desired extravasation site is the bone marrow. In other preferred embodiments, the desired extravasation site is a site of injury or inflammation.

[0060] In another embodiment, the invention provides a pharmaceutical composition comprising a population of cells produced by the methods of the invention and a pharmaceutically acceptable carrier.

[0061] In another embodiment, the present invention provides a kit for treating or ameliorating the effects of a condition, disease, or injury in a subject in need thereof, comprising a composition of the present invention packaged together with instructions for its use.

[0062] The kit may also include suitable storage containers, e.g., ampoules, vials, tubes, etc., for each of the pharmaceutical composition and other reagents, such as buffers, balanced salt solutions, etc., for use in administering the pharmaceutical composition to a subject. The pharmaceutical composition and other reagents may be present in the kit in any convenient form, e.g., in solution or powder form. The kit may further include instructions for use of the pharmaceutical composition. The kit may further include a packaging container, optionally having one or more compartments for containing the pharmaceutical composition and optional other reagents.

[0063] The present invention also provides a method for inducing and / or enhancing homing of a population of cells to a therapeutic target in a subject in need thereof, comprising the steps of: (a) providing to the population of cells a nucleic acid encoding a polypeptide that forces transient expression of a ligand that binds to a receptor at the therapeutic target; and (b) causing the population of cells to express the polypeptide, wherein upon expression of the polypeptide, homing of one or more cells in the population to the therapeutic target is induced and / or enhanced.

[0064] In some embodiments, the population of cells is any medically relevant population, for example, the population of cells is selected from the group consisting of stem cells, tissue progenitor cells, antigen-specific T cells, T regulatory cells, antigen-pulsed dendritic cells, NK cells, NKT cells, and leukocytes. In some embodiments, the population of cells is T-lymphocytes. In some embodiments, the population of cells is chimeric antigen receptor T cells.

[0065] In some embodiments, the population of cells has been expanded in culture prior to step (a).

[0066] In some embodiments, the therapeutic target can be any medically relevant target, such as a site of injury, inflammation, or tumor.

[0067] The embodiments described in this disclosure can be combined in various ways. Any aspect or feature described for one embodiment can be incorporated into any other embodiment mentioned in this disclosure. While various novel features of the principles of the present invention have been shown, described, and pointed out as applied to specific embodiments thereof, it should be understood that various omissions, substitutions, and modifications can be made by those skilled in the art without departing from the spirit of the present disclosure. Those skilled in the art will appreciate that the principles of the present invention can be embodied in forms other than the described embodiments, which are presented for purposes of illustration and not limitation. [Example]

[0068] Human mesenchymal stem cells (MSCs) hold great promise for cell therapy for skeletal diseases, but they lack expression of E-selectin ligands, which direct the homing of blood-borne cells to the bone marrow. Previously, we described a method for engineering E-selectin ligands on MSC surfaces by exofucosylating cells with fucosyltransferase VI (FTVI) and its donor sugar, GDP-fucose, and forcing transient surface expression of the potent E-selectin ligand HCELL, resulting in enhanced osteotropism of intravenously administered cells. Here, we sought to determine whether E-selectin ligands generated via FTVI-exofucosylation are distinct in identity and function from those generated by intracellularly expressed FTVI. To this end, in this example, we introduced synthetically modified mRNA encoding FTVI (FUT6-modRNA) into human MSCs. FTVI-exofucosylation (i.e., extracellular fucosylation) and FUT6-modRNA transfection (i.e., intracellular fucosylation) produced similar peak increases in cell surface E-selectin ligand levels, and shear-based functional assays showed comparable increases in tethering / rolling of E-selectin-expressing human endothelial cells. However, biochemical analysis revealed that intracellular fucosylation induced both intracellular and cell surface E-selectin ligand expression and also induced more sustained expression of E-selectin ligand compared with extracellular fucosylation. Notably, live imaging studies to assess the homing of human MSCs to the mouse calvaria revealed greater osteotropy after intravenous administration of intracellularly fucosylated cells compared with extracellularly fucosylated cells. This study is the first direct analysis of programmed E-selectin ligand expression in human MSCs by FTVI-mediated intracellular versus extracellular fucosylation. The differences in the biological effects of FTVI activity observed in these two settings may lead to new strategies to improve the efficacy of human MSCs in clinical applications. Example 1 Materials and Methods Human alpha 1,3 fucosyltransferase gene

[0069] Exemplary sequences for the human proteins FUT3, FUT4, FUT5, FUT6, and FUT7 are shown below. Exemplary nucleic acid sequences encoding such fucosyltransferases for expression may encode the full-length sequence (also shown below) or truncated portions thereof that retain enzymatic activity.

[0070] Human FUT3 cDNA sequence [ka] [ka] [ka]

[0071] Human FUT3 protein sequence [ka] [ka]

[0072] Human FUT4 cDNA sequence [ka] [ka] [ka]

[0073] Human FUT4 protein sequence [ka]

[0074] Human FUT5 cDNA sequence [ka] [ka] [ka]

[0075] Human FUT5 protein sequence [ka]

[0076] Human FUT6 cDNA sequence [ka] [ka]

[0077] Human FUT6 protein sequence [ka] [ka]

[0078] Human FUT7 cDNA sequence [ka] [ka]

[0079] Human FUT7 protein sequence [ka] Isolation and culture of human mesenchymal stem cells

[0080] Human cells were transferred to Partners Cancer Care Discarded bone marrow filter sets were obtained from normal human donors. Bone marrow cells were flushed from the filter sets using PBS + 10 U / ml heparin (Hospira). Mononuclear fractions were isolated using density gradient medium (Ficoll-Histopaque 1.077, Sigma-Aldrich) and cultured at 2–5 × 10 cells / ml in MSC medium (DMEM, 1 g / L glucose, 10% FBS from selected lots, 100 U / ml penicillin, 100 U / ml streptomycin). 6 The cells were suspended at 1000 cells / ml. 20 ml of the cell suspension was seeded into a T-175 tissue culture flask and incubated at 37°C, 5% CO2, and >95% humidity. After 24 hours, nonadherent cells were removed, the flask was rinsed with PBS, and fresh MSC medium was added. The MSC medium was then changed twice per week. Within 1–2 weeks, clusters of adherent MSCs were observed. When the confluence approached 80%, the cells were harvested, diluted 3–5 times in MSC medium, and plated into a new flask. For harvesting, the MSCs were rinsed twice with PBS and lifted with 0.05% trypsin and 0.5 mM EDTA. After centrifugation, the cell pellet was either resuspended in MSC medium for passage or washed with PBS for experimental use. MSC characterization and differentiation

[0081] MSCs were characterized by FACS staining for a panel of markers, including CD29, CD31, CD34, CD45, CD73, CD90, CD105, CD106, and CD166. Cell viability was measured using trypan blue exclusion. To induce osteogenic differentiation, cells were cultured in MSC medium plus 10 nM dexamethasone, 10 mM glycerophosphate, and 50 μg / ml L-ascorbate-2-phosphate. After 4 days, L-ascorbate-2-phosphate was removed, and the medium was changed every 3–4 days for a total of 14 days. To induce adipogenic differentiation, cells were cultured in DMEM containing 3 μg / L glucose, 3% FBS, 1 μM dexamethasone, 500 μM methylisobutylmethylxanthine (IBMX), 33 μM biotin, 5 μM rosiglitazone, 100 nM insulin, and 17 μM pantothenate. After 4 days, IBMX and rosiglitazone were removed, and the medium was changed every 3–4 days for a total of 14 days. As a negative control, MSCs were maintained in MSC medium for a total of 14 days, with the medium changed every 3–4 days. To visualize mineralized deposits, indicative of osteogenic differentiation, cells were stained with 2% alizarin red. After photomicrography, cells were destained using 10% cetylpyridinium chloride monohydrate, and the stained eluate was measured using a spectrophotometer at 595 nm. To visualize lipid deposits indicative of adipogenic differentiation, cells were stained with 0.3% Oil Red O and photomicrographs were taken. Modified mRNA synthesis

[0082] Modified mRNA (modRNA) was synthesized as previously described [Mandal, 2013]. Briefly, cDNA encoding human fucosyltransferase 6 (FUT6) was subcloned into a vector containing a T7 promoter, 5'UTR, and 3'UTR. A PCR reaction was performed to generate a template for in vitro transcription using HiFi Hotstart (KAPA Biosystems). 1.6 μg of purified PCR product containing the FUT6 ORF and 5' and 3'UTR was used as a template for RNA synthesis using the MEGAscript T7 kit (Ambion). 3'-O-Me-m7G(5')ppp(5')G ARCA cap analog (New England Biolabs), adenosine triphosphate and guanosine triphosphate (USB), 5-methylcytidine triphosphate, and pseudouridine triphosphate (TriLink Biotechnologies) were used for the in vitro transcription reaction. The modRNA product was purified using MEGAclear spin columns (Ambion), and aliquots were stored frozen for future use. A nuclear-destabilized EGFP (ndGFP) modRNA was similarly prepared as a negative control. modRNA transfection

[0083] ModRNA transfection was performed using Stemfect (Stemgent) according to the manufacturer's instructions. A tube was prepared containing 1 μg of modRNA in 60 μl of buffer and 2 μl of reagent in 60 μl of buffer. The two complexes were mixed together and incubated at room temperature for 15 minutes. The mixture was then transferred to 1 × 10 cells in 2 ml of MSC medium. 6 Following modRNA transfection, B18R interferon inhibitor (eBioscience) was used as a media supplement at 200 ng / ml. Measurement of FTVI production and specific activity

[0084] Recombinant FTVI enzyme was produced in CHO cells using established techniques [Borsig, 1998] using a cDNA encoding amino acids 35–359 of the FTVI protein sequence (SEQ ID NO: 8); this sequence omits the cytoplasmic and transmembrane regions of FTVI and encompasses the entire stem and catalytic domain of the enzyme. The specific activity of the purified enzyme was determined using a glycosyltransferase activity kit (R&D Systems) according to the manufacturer's instructions. Briefly, 0.1 μg of recombinant FTVI, 1 μL of ENTPD3 / CD39L3 phosphatase, 15 nmol of N-acetyl-D-lactosamine (V-labs Inc.), and 4 nmol of GDP-fucose (Sigma-Aldrich) were dissolved in 50 μL of reaction buffer (25 mM Tris, 10 mM CaCl2, and 10 mM MnCl2, pH 7.5) and incubated at 37°C for 20 minutes in a 96-well plate. A second reaction containing the same components except for recombinant FTVI was performed as a negative control. The reaction was terminated by adding 30 μL of malachite green reagent A and 100 μL of water to each well. Color was developed by adding 30 μL of malachite green reagent B to each well, followed by gentle agitation and incubation at room temperature for 20 minutes. The plate was read at 620 nm using a multiwell plate reader. A calibration curve was generated using phosphate standards, and the specific activity of the FTVI enzyme was determined to be 60 pmol / min / μg. FTVI exofucosylation

[0085] MSCs were collected, washed twice with PBS, and 2 × 10 cells were cultured in FTVI reaction buffer containing 20 mM HEPES (Gibco), 0.1% human serum albumin (Sigma), 1 mM GDP-fucose (Carbosynth), and 60 μg / ml purified FTVI enzyme in Hank's balanced salt solution (HBSS). 7The cells were resuspended at 1000 cells / ml. The cells were incubated at 37°C for 1 hour. For some experiments, a "buffer only" control was performed in the same format, but FTVI enzyme and GDP-fucose were omitted from the reaction. After the reaction, the cells were washed twice with PBS and used immediately for downstream experiments. Flow cytometry

[0086] 2.5 μl of HECA-FITC (Biolegend) or CsLex1-FITC (eBiosciences) was added to each well of a 96-well plate. MSCs were collected and plated at 1 × 10 in PBS + 2% FBS. 6 The cells were suspended at 1 / ml and 50 μl of the cell suspension was added to each well. After 30 minutes of incubation at 4°C, the plate was washed with 200 μl of PBS per well and resuspended in 200 μl of PBS. Fluorescence intensity was determined using a Cytomics FC500MPL flow cytometer (Beckman Coulter). Forced sLe X Time course of expression, subsequent FUT6-modRNA transfection and FTVI exofucosylation

[0087] MSCs were FUT6-modRNA transfected, FTVI exofucosylated, or left untreated, and aliquots were cultured in sLe cells using mAb HECA452. X The remaining cells were passaged into T-25 flasks (6 flasks per group). At 24-hour intervals, one flask from each group was harvested and flow cytometry was performed using HECA452. Cell surface sLe expression was analyzed. X A time course of expression was obtained by comparing the mean fluorescence intensity of HECA452 staining for each sample on a daily basis. Cell surface neuraminidase treatment and Western blot analysis

[0088] Untreated, FUT6-modRNA transfected MSCs (day 3) and exofucosylated MSCs (day 0) were cultured at 10 in HBSS + 0.1% BSA. 7 MSCs were then washed, counted, pelleted, and frozen at -80°C. Prior to use, the lysates were diluted to 100 ml and resuspended at 100 ml / ml and incubated with or without 0.1 U / ml Arthrobacter ureafasiens neuraminidase (Sigma) at 37°C for 45 minutes. MSCs were then washed, counted, pelleted, and frozen at -80°C. 5 Cells were prepared by adding 30 μl of twice-reducing SDS-sample buffer per cell and boiling for 10 minutes. Samples were then separated on a 7.5% Criterion Tris-HSC SDS-PAGE gel and transferred to a PVDF membrane. The membrane was blocked with 5% milk and then sequentially stained with mouse E-selectin human-Ig chimera (E-Ig, R&D Systems), rat anti-mouse E-selectin (clone 10E9.6, BD Biosciences), and goat anti-rat IgG conjugated to horseradish peroxidase (HRP, Southern Biotech). All staining and washing was performed in Tris-buffered saline + 0.1% Tween® 20 + 2 mM Tris-HSC. The blots were performed in CaCl2. Blots were visualized by chemiluminescence using Lumi-Light Western blotting substrate (Roche) according to the manufacturer's instructions. To confirm equal loading, membranes were then stained with rabbit anti-human beta-actin (ProSci) followed by goat anti-rabbit IgG-HRP (SouthernBiotech) and visualized by chemiluminescence as described. Immunoprecipitation of HCELL and E-selectin (E-Ig) pull-down

[0089] MSCs were transfected with FUT6-modRNA, exofucosylated with FTVI, or left untreated (control). Lysates were prepared in 2% NP40, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 20 μg / mL PMSF, and 1x protease inhibitor cocktail (Roche). Cell lysates were pre-cleared with protein G-agarose beads (Invitrogen). For CD44 immunoprecipitation, lysates were incubated with a cocktail of mouse anti-human CD44 monoclonal antibodies consisting of 2C5 (R&D Systems), F10-44.2 (Southern Biotech), 515, and G44-26 (both BD Biosciences). For E-selectin pull-down, lysates were incubated with mouse E-Ig in the presence of 2 mM CaCl. CD44 immunoprecipitates and E-Ig pulldowns were harvested using protein G-agarose beads, eluted via boiling in 1.5x reducing SDS-sample buffer, run on SDS-PAGE gels, and immunoblotted with anti-CD44 antibodies 2C5, G44-26, and F10-44.2, or anti-sLe X Western blotting was performed using antibody HECA452. Cell surface protein isolation

[0090] MSCs were biotinylated in flasks, and cell surface proteins were isolated using the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific) according to the manufacturer's instructions. Briefly, untreated or FUT6-modRNA-transfected MSCs were plated 3 days later and rinsed with PBS. 10 ml of amine-reactive EZ-Link Sulfo-NHS-SS-Biotin Reagent was added to each flask. The flasks were gently agitated for 30 minutes at 4°C, and the reaction was quenched with lysine. Cells were harvested, and a portion of the untreated MSCs was exofucosylated with FTVI. After the exofucosylation reaction, the cells were washed and lysed. Biotinylated cell surface proteins were isolated using NeutrAvidin Agarose beads and spin columns provided with the kit. The flow-through was collected as the non-biotinylated fraction, and bound proteins were eluted and collected as the biotinylated (cell surface) fraction. These fractions were run on a gel and Western blots were performed for E-Ig chimera and beta-actin as described.

[0091] Parallel plate flow chamber test Parallel-plate flow experiments were performed using a Bioflux-200 system and a 48-well low-shear microfluidic plate (Fluxion Biosciences). Microfluidic chambers were coated with 250 μg / ml fibronectin (BD Biosciences), and human umbilical vein endothelial cells (HUVECs, Lonza) were seeded and cultured in endothelial growth medium prepared from the EGM-2 BulletKit (EGM-2 medium, Lonza) until a confluent monolayer was formed. Four hours prior to the assay, HUVECs were activated with 40 ng / ml rhTNFα (R&D Systems) to induce E-selectin expression. FUT6-modRNA-transfected MSCs, FTVI exofucosylated MSCs, or untreated MSCs were cultured at 1.0–1.5 × 10 cells in EGM-2 medium. 6Rolling cells were suspended at 1.0 × 10 / ml and injected at flow rates initially representing a shear stress of 0.5 dynes / cm², increasing at 1-minute intervals to 1, 2, 4, 8, and 16 dynes / cm². The number of trapped rolling cells per field was counted for two separate 10-second intervals at each flow rate and averaged. Cell counts were determined visually by visually determining the total number of cells visible per field at the initial injection of 0.5 dynes / cm², and the number of trapped cells was calculated as 1.0 × 10 6 The data were corrected by expressing them as a percentage of the starting cell number normalized to the cell number in cells / ml. 6 The data are expressed as the number of captured rolling cells per mm2 normalized to cells / ml injected fluid. To determine the specificity of fucosylated cell binding, negative controls were performed using HUVECs not activated with TNFα and activated HUVECs blocked with anti-CD62E (E-selectin) antibody (clone 68-5H11, BD Pharmingen). The blocking antibody was suspended at 20 μg / ml in EGM-2 medium, injected onto HUVECs, and incubated for 20 minutes before washing and injection of fucosylated MSCs. Rolling velocity was calculated by measuring the distance traveled for all rolling cells at each 10-second interval, converting the distance to a velocity measured in μm / second for all rolling cells at each shear stress, and reporting the average rolling velocity. Vital dye staining and intravenous injection of human MSCs into mice

[0092] MSCs were harvested, transfected with FUT6-modRNA or ndGFP modRNA, and plated in T-175 flasks using B18R. Untreated MSCs were passaged simultaneously. After two days, untreated MSCs were harvested and split into FTVI-exofucosylated or "buffer only" control groups. FUT6- and ndGFP-transfected MSCs were collected directly. Aliquots of all samples were removed for flow cytometry analysis of HECA452. MSCs from each of the four treatments were split in two and plated at 1 x 10 cells / ml in PBS + 0.1% BSA. 6MSCs were suspended at 1000 cells / ml and stained with 10 μM Vybrant® DiD or Vybrant® DiI dye (Molecular Probes) for 20 minutes at 37°C. Cells were washed twice and 1:1 reciprocal mixtures (1:1 mixture of FUT6-mod RNA-transfected MSCs and ndGFP control-transfected MSCs, and 1:1 mixture of FTVI-exofucosylated MSCs and buffer control-treated MSCs) were prepared. Each cell combination was injected retroorbitally into pairs of immunocompetent BL / 6 mice, with the membrane dye combinations exchanged between each pair of mice. Subsequently, 2 nmol of Angiosense 750 (PerkinElmer) was injected per mouse to allow simultaneous visualization of blood vessels. Aliquots of the cell mixture injected into each mouse were stained with HECA452-FITC and imaged on glass slides to confirm the efficacy of FUT6-mod or FTVI-exofucosylated MSCs. A minimum of 20 such images (average 450 cells) were counted to obtain accurate homing ratios of DiD- and DiI-labeled MSCs for each mouse. If the homing ratio differed from 1:1, a correction count was calculated, and the homing ratio obtained from the in vivo images was adjusted accordingly. In vivo confocal and two-photon fluorescence microscopy

[0093] In vivo MSC homing to calvarial bone marrow was imaged using a custom-built video-rate laser scanning microscope designed for live animal imaging under isoflurane anesthesia. The head was shaved and a skin flap surgically opened to expose the calvaria. The calvarial region was wetted with saline and placed directly under a 60x 1.0 NA water immersion objective (Olympus, Center Valley, PA). Image stacks were acquired at 30 frames per second with frame averaging to enhance the signal-to-noise ratio. DiI-labeled MSCs, DiD-labeled MSCs, and Angiosense 750-labeled blood vessels were imaged using a confocal detection scheme. Second-harmonic generation of bone collagen was performed using 840 nm light from a femtosecond pulsed Maitai laser (Coherent, Inc., Santa Clara, CA). Cells could be detected to a depth of approximately 200 μm within the tissue. Imaging was performed approximately 2 and 24 hours after implantation. Between imaging sessions, the scalp flap was sutured closed and the mice were allowed to recover.The study was conducted under approval by the Massachusetts General Hospital Institutional Animal Care and Use Committee and in accordance with the National Institutes of Health guidelines for the care and use of animals.

[0094] In vivo imaging analysis Calvarial images were collected and quantified as 3D stacks [Mortensen, 2013]. For quantification, the number of DiD and DiI cells at 20 representative imaging locations across the calvarial marrow was manually counted for each mouse. Analysis was performed blind, with counting events corresponding to a minimum diameter of approximately 10 μm to exclude debris from the analysis, and signals were used to exclude autofluorescent events in both the DiD and DiI channels (those with an intensity in the primary channel less than approximately 2× the intensity in the other channel). Extravasated cells were defined as cells completely distinct from Angiosense-labeled blood vessels (i.e., no part of the cell overlapped with any part of either blood vessel). The ratio of DiD-to-DiI-stained cells counted in each mouse was calculated and compared for each pair of mice, with equivalent homing assigned a baseline ratio of 1. Therefore, the fold change in homing of treated MSCs compared to control MSCs was calculated for each pair of mice to provide a relative measure of homing efficacy. Eight mice (four mouse pairs) representing four different primary MSC lines were imaged per treatment. Example 2 MSC characterization

[0095] Primary bone marrow-derived MSCs were evaluated for a panel of markers, including CD29, CD31, CD34, CD45, CD73, CD90, CD105, CD106, and CD166. MSCs were uniformly positive for the MSC markers CD29, CD44, CD73, CD90, and CD105, faint for CD106, and negative for the endothelial cell marker CD31 and the hematopoietic markers CD34 and CD45 (Figure 1A). This marker expression profile was consistent across all seven primary MSC lines tested (Figure 1B). Two primary MSC lines were tested for their ability to differentiate into adipogenic and osteogenic lineages (representative images are shown in Figure 1C). Example 3 sLe X Surface expression peaks 2–3 days after FUT6-modRNA transfection and declines more slowly than in the case of FTVI exofucosylation.

[0096] To determine the optimal time point for cell surface E-selectin ligand expression, we analyzed sLe by flow cytometry between FTVI exofucosylation of MSCs and FUT6-modRNA transfection. X The kinetics of surface expression were compared. As expected, exofucosylated cells expressed the maximum surface sLe immediately after treatment. X This reached a maximum of 1000 sLe2 at 2 days post-transfection, which then declined to 40% by 24 hours and returned to near-zero baseline levels (i.e., similar to native MSC reactivity) by 48 hours. In contrast, FUT6-modRNA-transfected cells showed a maximum cell surface sLe2 at 2 days post-transfection. X The expression level reached 1000 and remained high until day 3, after which it gradually decreased (Fig. 2). X Based on these kinetics of expression, all experiments with exofucosylated cells were performed immediately after treatment, whereas experiments with FUT6-modRNA-transfected cells were performed 2–3 days after transfection. Example 4 sLe induced by intracellular and extracellular FTVI fucosylation X Surface expression is similar and consistent across multiple primary MSC lines and does not alter MSC properties

[0097] To assess the overall degree of fucosylation of cell surface glycans using both methods, we analyzed total cell surface sLe by flow cytometry. X The levels of surface sLe were analyzed in both intracellular and extracellular fucosylated cells. X A second anti-sLe revealed an approximately 2-log increase in expression (Figure 3A), a result that rules out clone-specific bias. X The results were confirmed using mAb clones (Figure 3A). Although some variation was observed between MSC primary cultures, on average, cell surface sLe XThe increase in β-amyloid activity was similar for both methods when five independent primary MSC lines were tested (Figure 3B). To determine whether either method of FTVI fucosylation affected MSC biological characteristics, we examined several key characteristics before and after fucosylation (Figure 4A-4D). We observed that MSC viability was not significantly reduced by intracellular or extracellular fucosylation (Figure 4A), and that a panel of MSC markers was unchanged either when measured immediately after fucosylation (Figure 4B, 4C) or when cultured for additional passages (i.e., 5-11 days) (Figure 4C). Finally, we differentiated treated cells toward the osteoblastic or adipogenic lineage, but no visible differences in differentiation were observed. Quantification of osteoblastic differentiation revealed no significant differences between intracellularly and extracellularly fucosylated MSCs and their respective controls, as well as no reduction compared to untreated MSCs (Figure 4D). Example 5 Comparative analysis of E-selectin ligand glycoproteins generated by intracellular and extracellular fucosylation

[0098] To analyze the identity and cellular localization of the E-selectin ligand glycoprotein generated by FUT6-modRNA transfection and FTVI-exofucosylation, we performed Western blots using E-selectin-Ig chimera (E-Ig) as a probe. Lysates from extracellularly fucosylated MSCs showed an E-Ig-reactive band at approximately 85 kD, a size corresponding primarily to HCELL [Sackstein, 20098], and an uncharacterized glycoprotein at approximately 60 kD (Figure 5A). To assess whether the approximately 85 kD band was indeed HCELL, we immunoprecipitated CD44 and blotted with HECA452, and conversely, isolated the E-selectin ligand using E-Ig and blotted with CD44 (Figure 6A-B). Although both HCELL and the approximately 60 kD band were similarly present in lysates of intracellularly fucosylated MSCs, a larger molecular weight E-Ig-reactive band was also observed at much greater intensity in these lysates, suggesting that additional glycoprotein substrates are accessible for fucosylation when FTVI is present in its native intracellular context (Figure 5A). To determine the cellular localization of E-Ig-reactive proteins, neuraminidase treatment of intact cells was performed to separate sLe from all cell surface glycoproteins. X As expected, no E-Ig-reactive glycoproteins remained after neuraminidase treatment of extracellularly fucosylated cells, indicating that all were extracellularly localized. In intracellularly fucosylated cells (day 3), all of the detectable E-Ig-reactive proteins of approximately 60 kD and approximately 85 kD were extracellular, but some of the larger E-Ig-reactive proteins were still present after neuraminidase treatment, suggesting intracellular localization (Figure 5B). This trend was supported by cell surface biotinylation experiments (Figure 7), which revealed that the approximately 60 kD and approximately 85 kD bands accounted for a larger proportion of accessible cell surface proteins compared to the larger E-Ig-reactive proteins. Example 6 Intracellular and extracellular fucosylation similarly enable E-selectin ligand-mediated MSC capture, tethering, and rolling under fluid shear conditions

[0099] sLe X Because fucosylation is a critical binding determinant for E-selectin, the dramatic increase in HECA452 and csLex1 reactivity suggests that both intracellular and extracellular fucosylation enable functional E-selectin binding activity for treated MSCs. To directly assess E-selectin binding activity, we examined the ability of fucosylated and untreated MSCs to capture, tether, and roll under fluid shear conditions on HUVEC monolayers stimulated to express E-selectin by treatment with TNFα. Untreated MSCs showed little to no interaction with stimulated HUVECs at any shear stress level, consistent with the lack of E-selectin ligand expression. In contrast, both intracellularly and extracellularly fucosylated MSCs exhibited greatly enhanced ability to capture, tether, and roll on TNFα-stimulated HUVEC monolayers at shear stress levels up to 4 dynes / cm² (Figure 8A). No significant differences were observed in the number of rolling cells (Figure 8A) or rolling velocity (Figure 8B) between extracellularly fucosylated and extracellularly fucosylated MSCs, and no significant differences were observed in the surface sLe observed by FACS. X These results suggest that similar increased levels of E-selectin correctly predict the functional improvements corresponding to the E-selectin ligand activity obtained with treated MSCs. Unstimulated HUVECs or HUVECs treated with an anti-E-selectin blocking monoclonal antibody did not support capture, tethering, or rolling interactions with fucosylated MSCs, confirming that these interactions were solely mediated by E-selectin. Example 7 Both intracellularly and extracellularly fucosylated MSCs accumulate in the calvarial bone marrow more efficiently than untreated MSCs

[0100] Cell surface sLe observed by FACS XThe dramatic increases in E-Ig reactivity observed by Western blot and in the capture / tethering and rolling observed in TNFα-stimulated HUVECs collectively indicate that both intracellular and extracellular fucosylation can generate agonistic E-selectin ligands on MSCs. To determine whether these differences in E-selectin ligands are functionally relevant in vivo, we examined their in vivo bone marrow-homing properties using intravital confocal multiphoton microscopy for cell tracking in the calvaria of mouse hosts (Levy, 2013; Mortensen, 2013). Intracellularly or extracellularly fucosylated MSCs, along with corresponding nonfucosylated control cells, were stained with the cell surface dyes DiD or DiI, respectively, to prepare 1:1 reciprocal cell mixtures (treated vs. control). Pairs of mice were transplanted with each cell combination, and the membrane dye combinations were exchanged between each pair of mice. Aliquots of the cell mixture injected into each mouse were stained with HECA452 and imaged on glass slides to confirm the effectiveness of fucosylation and obtain accurate initiation rates (Figure 9). Approximately 2 hours and again 24 hours after transplantation, the calvaria were imaged (Figure 10A), and DiD and DiI events were counted. Compared to control MSCs, both intracellularly and extracellularly fucosylated MSCs demonstrated significantly increased osteotropism (i.e., accumulation in bone) 2 hours after transplantation (Figure 10B). When the same mice were imaged 24 hours after transplantation, a similar trend was observed, with an even more significant increase in cell number observed for intracellularly fucosylated MSCs compared to intracellularly fucosylated MSCs (Figure 10C). Example 8 Intracellularly fucosylated MSCs demonstrate significantly greater extravasation from calvarial vessels into the bone marrow parenchyma 24 hours after transplantation

[0101] Extravasation of transplanted cells into the bone marrow parenchyma is a prerequisite for engraftment. To assess the extent of extravasation, we injected a near-infrared vascular dye (Angiosense 750) to visualize mouse blood vessels and performed multi-stack imaging. We imaged calvaria 24 hours after transplantation to identify DiI- and DiD-stained cells that clearly extravasated from blood vessels into the surrounding bone marrow space (Figure 11A). We found that both intracellularly and extracellularly fucosylated MSCs exhibited significantly enhanced penetration into the bone marrow parenchyma compared with control MSCs (Figure 11B). Furthermore, clear differences in extravasation were observed between the two treatments: 24 hours after transplantation, intracellularly fucosylated MSCs appeared to extravasate twice as much as extracellularly fucosylated MSCs (Figure 11B). These findings suggest that the sustained (i.e., longer than 2 days) presence of E-selectin ligands upon FUT6-modRNA transduction (Figure 2) results in functional improvements in cell homing and extravasation in an in vivo situation. Example 9 Discussion and Conclusion Consideration

[0102] MSCs are a promising avenue for cell therapy with significant potential for clinical impact. Over 500 past and current clinical trials worldwide have utilized MSCs to treat a wide range of conditions, including bone diseases (e.g., osteoporosis, osteogenesis imperfecta), autoimmune diseases (e.g., lupus, multiple sclerosis), and inflammatory diseases (e.g., myocardial infarction, ulcerative colitis) [clinicaltrials.gov, accessed December 2015]. However, while MSC transplants are well tolerated, clinical outcomes have generally been disappointing [Griffin, 2013; Galipeau, 2013]. A major unresolved challenge limiting the clinical efficacy of MSCs is effectively delivering transplanted MSCs to their intended target site(s). While direct injection of MSCs into injured / diseased organs is possible for some indications, this approach is invasive and can result in collateral tissue damage. Furthermore, for certain organs or multifocal or systemic conditions, local injection is difficult to implement, and strategies are needed to optimize vascular delivery of cells to enable effective site-specific localization.

[0103] One of the major drawbacks limiting MSC homing is the lack of E-selectin ligand expression. In attempts to engineer MSCs with E-selectin ligands, various approaches have been used, such as covalently linking peptides to the cell membrane [Cheng, 2012] and E-selectin ligand fusion proteins [Lo, 2016] or sLe X Non-covalent coupling of coated polymer beads [Sarkar, 2011] has been utilized, but perhaps the most physiologically relevant approach is to couple terminal sialylated lactosamines to the canonical selectin binding determinant, sLe. XOur approach harnesses the power of the inherently potent and specific human alpha(1,3)-fucosyltransferase enzyme, which has the ability to convert fucosyltransferase into fucosyltransferase. We previously described the use of purified FTVI to exofucosylate the cell surface of MSCs, thus generating the E-selectin ligand HCELL and improving their homing to bone [Sackstein, 2009]. Exofucosylation has also been employed to enhance selectin-mediated homing and engraftment of other cell types, including umbilical cord hematopoietic cells [Xia, 2004; Wan, 2013; Popat, 2015], regulatory T cells [Parmar, 2015], and neural stem cells [Merzaban, 2015]. In contrast, the use of modRNA to generate fucosyltransferase intracellularly in MSCs is new and relatively unexplored. In the only study to date, human MSCs were cotransfected with modRNAs encoding FTVII, P-selectin glycoprotein ligand-1 (PSGL-1), and the anti-inflammatory cytokine interleukin-10 (IL-10). When these triple-transfected cells were xenotransplanted into mice, a slight enhancement of bone marrow homing was reported, along with modest improvements in a skin inflammation model [Levy, 2013] and an experimental autoimmune encephalomyelitis model [Liao, 2016]. However, due to the nature of the experimental design (i.e., cotransfection with modRNAs to coexpress three genes) and methodological differences (different fucosyltransferases, different preclinical models), it is difficult to compare the results with those from other studies employing exofucosylation. Notably, it was not possible to determine from these studies whether the E-selectin ligand generated by modRNA transfection is similar in identity and function to the E-selectin ligand generated by the action of extracellular fucosyltransferases and whether any differences in the resulting homing efficiency would be revealed.

[0104] Our results herein demonstrate that sLe XAcross multiple primary cultures of human MSCs, we demonstrate that the intracellular and extracellular fucosylation methods are equally potent for generating cell surface E-selectin ligands, as measured by fucosylation levels (i.e., as assessed by reactivity to mAb HECA452) and confirmed by assessing E-selectin-mediated capture / tethering / rolling activity on cytokine-stimulated HUVECs under thermodynamic shear conditions. The amount and cellular localization of certain E-selectin ligand glycoproteins produced differed slightly between the two methods, with intracellular fucosylation resulting in some additional E-selectin-binding glycoproteins present both intracellularly and extracellularly. Additional intracellular proteins are novel sLe proteins normally localized intracellularly. X Whether these proteins represent retention glycoproteins or precursors for transport to the cell surface (i.e., proteins that undergo further post-translational modification, are stored in granules, or are in the process of being shuttled to the cell surface) remains to be determined. The most striking difference between the two methods was the kinetics of E-selectin ligand presentation at the cell surface. X was observed immediately after extracellular fucosylation and rapidly decreased within 1–2 days, whereas intracellular fucosylation was observed after sLe X The exofucosylation peaked at 48 hours and then declined more slowly. Furthermore, while both methods significantly increased osteotropism compared with control MSCs, a greater increase in overall bone marrow homing, and particularly in transmigration, was observed for the intracellularly fucosylated cells in vivo at 24 hours after transplantation. Given the fact that exofucosylation occurred immediately after exofucosylation or 2 days after modRNA transfection, significantly different levels of E-selectin ligand remaining on the cell surface may contribute to these differences at 24 hours. Further studies are warranted to determine the molecular basis for this effect, but it may also be related to increased accessibility of glycan acceptors in the Golgi and / or differential membrane distribution of intracellular glycosylation products.

[0105] Our findings are important for informing future clinical applications using human MSCs and other cells of interest (e.g., stem cells, tissue progenitor cells, or other types of leukocytes). Both FTVI exofucosylation and FUT6-modRNA transfection are ideal glycoengineering strategies because they are simple, transient, and non-integrating. In addition to the longer duration of E-selectin ligand expression and associated improvements in homing and transmigration properties following intracellular glycosylation described herein, a practical advantage of this approach is that the FTVI enzyme and GDP-fucose are cellular products, thus eliminating the labor and expense associated with purifying soluble recombinant enzymes and synthesizing GDP-fucose. Furthermore, because the FTVI enzyme is localized in its native cellular context (i.e., embedded in the Golgi membrane), additional acceptor substrates are accessible for fucosylation. On the other hand, practical advantages of extracellular fucosylation include the rapidity of the procedure (thus avoiding further culturing of the cells), avoidance of potential disruption of the Golgi glycosylation network, and the absence of risks associated with introducing nucleic acids into cells, such as, but not limited to, activation of the cellular antiviral defense mechanism. Furthermore, when considering the fucosylation of other clinically relevant cells (i.e., non-MSCs), exofucosylation can be readily applied to any cell type that retains sialylated lactosamine on its cell surface, which is consistent with the use of cell surface sLe X A cell type or cell surface that can be easily transfected with a nucleic acid (e.g., modRNA) encoding the fucosyltransferase(s) required to enforce expression. X This is in contrast to intracellular fucosylation (or other intracellular glycosyltransferase modifications), which are restricted to cell types in which nucleic acids encoding the relevant fucosyltransferase(s) required to enforce expression can be introduced by other means (e.g., transduction via viral vectors). However, in those cells that can be transfected or transduced, cell surface sLe XIntroduction of the relevant nucleic acid sequence encoding the glycosyltransferase(s) necessary to force expression results in cell surface sLe X It can be combined with cell surface (extracellular) fucosylation to create and / or enhance expression. Such combinatorial strategies are encompassed within the scope of the present invention.

[0106] The present inventors have found that combining intracellular fucosylation via the introduction of nucleic acids (e.g., modRNAs) encoding fucosyltransferases with the fucosyltransferase-mediated exofucosylation process can result in substantially higher (and more prolonged) expression of E-selectin ligand activity in cells. In many cases, cell surface sLe X Introduction of a nucleic acid encoding a glycosyltransferase to force expression of fucosylation may be useful for a diverse population of clinically relevant cell types, including, for example, embryonic stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs). Adult stem cells include stem cells obtained from any clinically relevant site, including bone marrow, umbilical cord blood, adipose tissue, placental tissue, skin, muscle, liver, pancreas, neural tissue, eye tissue, and indeed stem cells from any cell type derived from ectodermal, endodermal, or mesenchymal cell lineages. Thus, depending on the particular clinical application(s), the utility of intracellular or extracellular fucosylation approaches may be preferred.

[0107] It is now clear that maximizing E-selectin interactions through fucosylation is an effective strategy for improving bone homing and may be useful for treating a wide range of medical disorders, including, but not limited to, inflammatory disorders (e.g., autoimmune diseases such as diabetes and rheumatoid arthritis), degenerative diseases (e.g., osteoporosis), cardiovascular disease, ischemic conditions, and cancer. However, MSCs and other cells of interest (e.g., other types of stem cells, tissue progenitors, or leukocytes) may be modified in other ways to further improve homing and / or differentiation into relevant cell types. For example, attempts have been made to improve MSC retention on bone surfaces by immobilizing alendronate to MSCs [Yao, 2013], improving cell migration to tissues by upregulating the expression of chemokine receptors (e.g., CXCR4) [Wynn, 2004; Shi, 2007; Jones, 2012], and improving firm adhesion and differentiation to bone by increasing integrin levels or activity [Kumar, 2007; Srouji, 2012; Hamidouche, 2009]. It seems reasonable for future translational efforts to combine multiple homing and differentiation approaches in specific and stepwise fashions to enhance the involvement of MSCs or other relevant cells at each stage of the homing, engraftment, and differentiation process. Thus, fucosylation can be used as an important aspect of combinatorial approaches to maximize the clinical utility of all cell-based therapies.

[0108] The inventors further demonstrate that maximizing fucosylation, particularly E-selectin interaction via modRNA processing or other means of introducing nucleic acid sequences encoding relevant α(1,3)-fucosyltransferases, may be beneficial in treating a variety of conditions, including direct tissue injury (e.g., burns, trauma, decubitus ulcers, etc.), ischemic / vascular events (e.g., myocardial infarction, stroke, shock, hemorrhage, coagulation disorders, etc.), infectious diseases (e.g., cellulitis, pneumonia, meningitis, SIRS, etc.), neoplasia (e.g., breast cancer, lung cancer, lymphoma, etc.), immunological / autoimmune conditions (e.g., graft-versus-host disease, multiple sclerosis, diabetes, inflammatory bowel disease, lupus erythematosus, rheumatoid arthritis, psoriasis, etc.), degenerative diseases (e.g., osteoporosis, osteoarthritis, Alzheimer's disease, etc.), congenital / genetic diseases, and the like. (e.g., epidermolysis bullosa, osteogenesis imperfecta, muscular dystrophy, lysosomal storage diseases, Huntington's disease, etc.), adverse drug reactions (e.g., drug-induced hepatitis, drug-induced cardiac damage, etc.), toxic insults (e.g., radiation exposure, chemical exposure, alcoholic hepatitis, alcoholic pancreatitis, alcoholic cardiomyopathy, cocaine cardiomyopathy, etc.), metabolic disorders (e.g., uremic pericarditis, metabolic acidosis, etc.), iatrogenic conditions (e.g., radiation-induced tissue injury, surgery-related complications, etc.), and / or idiopathic processes (e.g., amyotrophic lateral sclerosis, Parsonage-Turner syndrome, etc.).

[0109] The present disclosure is further directed to treating diseases, disorders, or conditions in which E-selectin is expressed in the endothelial bed of affected tissues and / or L-selectin-expressing leukocytes infiltrate / accumulate in affected tissues by maximizing E-selectin interactions via fucosylation, particularly using modRNA processes. As previously mentioned, E-selectin and L-selectin bind to sialylated, fucosylated carbohydrates, respectively, and forced expression of these sialofucosylated glycan structures on the cell surface serves to program binding to these selectins. Thus, the present disclosure describes methods for increasing homing to target tissues by increasing the expression of E-selectin ligands on administered cells; and further describes methods for increasing the expression of strong E-selectin and L-selectin ligands (such as HCELL) on administered cells to promote adhesion to E-selectin on vascular endothelial cells and / or to L-selectin on tissue-infiltrating leukocytes within diseased tissues, providing a means for increasing cell retention / adhesion within the relevant tissue microenvironment where a biological effect is intended. In general, the methods described herein have utility for improving the outcome of any cell-based therapeutic approach, whether in immunotherapy applications (e.g., administration of culture-expanded antigen-specific T cells and / or culture-expanded NK cells for cancer or infectious disease applications, administration of culture-expanded chimeric antigen receptor [CAR] T cells, administration of antigen-pulsed dendritic cells, etc.), immunomodulatory / immunosuppressive therapeutic applications (e.g., administration of culture-expanded regulatory T cells [Tregs], administration of antigen-pulsed dendritic cells, administration of mesenchymal stem cells, administration of culture-expanded NKT cells, etc.), or tissue repair / regenerative medicine applications (e.g., use of stem and / or progenitor cells or other tissue repair cells for tissue regeneration / repair; use of culture-expanded stem cells and / or culture-expanded progenitor cells for tissue regeneration / repair).With regard to their utility in regenerative medicine applications, it is understood that the administered cells can themselves contribute to regenerating the target tissue by long-term engraftment (with concomitant proliferation / differentiation) to produce tissue-specific cells (e.g., in hematopoietic stem cell transplantation for blood cell production), and / or can provide a tissue repair / repair effect to tissue-resident cells without long-term engraftment or differentiation (e.g., by providing a trophic effect to stimulate resident stem / progenitor cells to repair damaged tissue and / or by attenuating inflammatory processes that promote injury and hinder repair). All applications for all indications described herein can be used alone or in combination with promoting agents (e.g., growth factors, tissue scaffolds, etc.). Direct tissue injury (e.g., burns, trauma, fractures, bone deformities, decubitus ulcers, etc.), ischemic / vascular events (e.g., myocardial infarction, stroke, shock, hemorrhage, coagulation disorders, etc.), infections (e.g., cellulitis, pneumonia, meningitis, cystitis, sepsis, SIRS, etc.), neoplasia (e.g., breast cancer, lung cancer, prostate cancer, renal cell carcinoma, lymphoma, leukemia, etc.), immunological / autoimmune conditions (e.g., acute or chronic GVHD, multiple sclerosis, diabetes, inflammatory bowel disease [e.g., Crohn's disease, ulcerative colitis], rheumatoid arthritis, psoriasis, etc.), degenerative diseases (e.g., osteoporosis, osteoarthritis, intervertebral disc degeneration, Alzheimer's disease, atherosclerosis, etc.), congenital / genetic diseases (e.g., epidermolysis bullosa, osteogenesis imperfecta, muscular dystrophy, lysosomal storage disorders, Huntington's disease, etc.), adverse drug reactions Any disease, disorder or condition, tissue injury / damage or neoplastic condition with associated inflammation (e.g., acute and / or chronic), including but not limited to those initiated by (e.g., chemotherapy-induced tissue / organ toxicity, radiation therapy toxicity, drug-induced hepatitis, drug-induced cardiac injury, etc.), toxic insult (e.g., radiation exposure, chemical exposure, alcoholic hepatitis, alcoholic pancreatitis, alcoholic cardiomyopathy, cocaine cardiomyopathy, etc.), metabolic abnormality (e.g., uremic pericarditis, metabolic acidosis, etc.), iatrogenic condition (e.g., radiation-induced tissue injury, surgery-related complications, etc.), and / or idiopathic process (e.g., amyotrophic lateral sclerosis, Parsonage-Turner syndrome, etc.), can be treated by the methods described herein.Other general and specific diseases, disorders or conditions that can be treated by the methods described herein include, but are not limited to: acute leukemias (e.g., acute biphenotypic leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and acute undifferentiated leukemia); Myelodysplastic syndromes, such as amyloidotic chronic myelomonocytic leukemia (CMML), refractory anemia (RA), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transition (RAEB-T) and refractory anemia with ringed sideroblasts (RARS); Myeloproliferative disorders, such as acute myelofibrosis, myeloid metaplasia of unknown cause (myelofibrosis), essential thrombocythemia, chronic myeloid leukemia, and polycythemia vera; phagocytic disorders, such as Chediak-Higashi syndrome, chronic granulomatous disease, leukocyte adhesion deficiency, myeloperoxidase deficiency, neutrophil actin deficiency, and reticulocellular dysplasia; Lysosomal storage diseases, such as adrenoleukodystrophy, alpha-mannosidosis, Gaucher disease, Hunter syndrome (MPS-II), Hurler syndrome (MPS-IH), Krabbe disease, Marote-Lamy syndrome (MPS-VI), metachromatic leukodystrophy, Morquio syndrome (MPS-IV), mucolipidosis II (I-cell disease), mucopolysaccharidosis (MPS), Niemann-Pick disease, Sanfilippo syndrome (MPS-III), Shy syndrome (MPS-IS), Sly syndrome, beta-glucuronidase deficiency (MPS-VII), and Wolman disease; Genetic red blood cell abnormalities, such as beta thalassaemia, Blackfan Diamond anemia, pure red cell aplasia, and sickle cell disease; genetic platelet abnormalities, e.g., amegakaryocytosis / congenital thrombocytopenia, gray platelet syndrome; Solid organ malignancies, such as brain tumors, Ewing's sarcoma, neuroblastoma, ovarian cancer, renal cell carcinoma, lung cancer, breast cancer, gastric cancer, esophageal cancer, skin cancer, oral cancer, endocrine cancer, liver cancer, biliary system cancer, pancreatic cancer, prostate cancer, and testicular cancer; Other applications include bone marrow transplantation, heart disease (myocardial infarction), liver disease, muscular dystrophy, Alzheimer's disease, Parkinson's disease, spinal cord injury, disc disease / degeneration, bone disease, fractures, stroke, peripheral vascular disease, head trauma, bullous disease, mitochondrial disease, ex vivo and in vivo expanded stem and progenitor cell populations, in vitro fertilization applications and expansion, Hematopoietic Rescue Situations (intense chemo / radiation), various tissue origins, Stem and progenitor cells obtained from sources, applications in humans and animals, and limb regeneration, reconstructive surgical procedures / indications, alone or in combination with enhancers; Chronic leukemias, such as chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), juvenile chronic myeloid leukemia (JCML) and juvenile myelomonocytic leukemia (JMML), Stem cell disorders, such as aplastic anemia (severe), congenital cytopenias, dyskeratosis congenita, Fanconi anemia and paroxysmal nocturnal hemoglobinuria (PNH); Lymphoproliferative disorders, such as Hodgkin's disease, non-Hodgkin's lymphoma, and prolymphocytic leukemia; Histiocytic disorders, such as familial erythrophagocytic lymphohistiocytosis, hemophagocytosis, hemophagocytic lymphohistiocytosis, histiocytosis X, and Langerhans cell histiocytosis; Congenital (genetic) immune system disorders, such as absence of T and B cells, absence of T cells, normal B-cell SCID, ataxia-telangiectasia, bare lymphocyte syndrome, common variable immunodeficiency, DiGeorge syndrome, Kostmann syndrome, leukocyte adhesion deficiency, Omenn syndrome, severe combined immunodeficiency (SCID), SCID with adenosine deaminase deficiency, Wiskott-Aldrich syndrome, and X-linked lymphoproliferative disorder; Other genetic disorders, such as cartilage-hair hypoplasia, ceroid lipofuscinosis, congenital erythropoietic porphyria, familial Mediterranean fever, Glanzmann thrombasthenia, Lesch-Nyhan syndrome, osteopetrosis and Sandhoff disease; Plasma cell disorders, such as multiple myeloma, plasma cell leukemia, and Waldenström's macroglobulinemia; Autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, ankylosing spondylitis, diabetes mellitus and inflammatory bowel disease. Joint and bone diseases / conditions, such as intervertebral disc degeneration, synovial disease, cartilage degeneration, cartilage trauma, cartilage tears, arthritis, fractures, bone deformities, bone reconstruction, osteogenesis imperfecta, congenital bone diseases / conditions, genetic bone diseases / conditions, osteoporosis, osteopetrosis, hypophosphatasia, metabolic bone diseases, etc. Skin / soft tissue diseases and conditions such as bullous diseases, psoriasis, eczema, epidermolysis bullosa, ulcerative skin conditions, soft tissue deformities (including post-operative skin and soft tissue deformities), plastic / reconstructive surgery indications, etc.

[0110] Generally, associated inflammatory symptoms include, but are not limited to, fever, pain, edema, congestion, erythema, bruising, tenderness, rigidity, swelling, chills, respiratory distress, decreased blood pressure, high blood pressure, nasal congestion, headache, respiratory distress, fluid retention, blood clots, loss of appetite, weight loss, polyuria, nocturia, anuria, dyspnea, dyspnea with exertion, muscle weakness, sensory changes, increased heart rate, decreased heart rate, arrhythmia, polydipsia, granuloma formation, fibrinous, purulent, non-viscous serous fluid, or ulcers. The actual symptoms associated with acute and / or chronic inflammation are well known and can be determined by one of skill in the art by considering factors including, but not limited to, the location of the inflammation, the cause of the inflammation, the severity of the inflammation, the affected tissue or organ, and associated disorders.

[0111] Specific patterns of acute and / or chronic inflammation are seen during certain conditions in the body, such as when inflammation occurs at epithelial surfaces or involves pyogenic bacteria. For example, granulomatous inflammation is inflammation resulting from the formation of granulomas resulting from a limited number of diseases, including but not limited to tuberculosis, leprosy, sarcoidosis, and syphilis. Suppurative inflammation is inflammation resulting in large amounts of pus, which consists of neutrophils, dead cells, and fluid. Infections with pyogenic bacteria, such as Staphylococcus, are characteristic of this type of inflammation. Serous inflammation is inflammation resulting from the exudation of large amounts of non-viscous serous fluid, typically produced by serous mesothelial cells but derived from plasma. Skin blisters exemplify this pattern of inflammation.

[0112] Ulcerative inflammation is inflammation resulting from necrotic loss of tissue from the epithelial surface, exposing the underlying layers and forming an ulcer.

[0113] Acute and / or chronic inflammatory symptoms can be associated with a large, unrelated group of disorders underlying various diseases and disorders. The immune system is often involved in many immune system disorders that result in abnormal inflammation, including acute and / or chronic inflammatory disorders, as evidenced in allergic reactions, arthritis, and some myopathies. Non-immune diseases whose etiological origins lie in acute and / or chronic inflammatory processes include cancer, atherosclerosis, and ischemic heart disease. Non-limiting examples of disorders that present with acute and / or chronic inflammation as a symptom include acne, acid reflux / heartburn, age-related macular degeneration (AMD), allergies, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma, atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, bullous pemphigus, burns, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervix, and the like. ductitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD) (and / or its acute exacerbation), liver cirrhosis, colitis, congestive heart failure, conjunctivitis, drug-induced tissue injury (e.g., cyclophosphamide-induced cystitis), cystic fibrosis, cystitis, colds, dacryoadenitis, decubitus ulcers, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcers, and gastrointestinal diseases Disease, eczema, emphysema, encephalitis, endocarditis, endocrine disorders, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibroplasia, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's chorea, hyperlipidemic pancreatitis, hypertension, ileitis, infections, inflammatory bowel disease, inflammatory cardiac hypertrophy, inflammatory neuropathies, insulin resistance, interstitial cystitis, interstitial nephritis, iris inflammation, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, macular degeneration, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), migraine, mucositis, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, neuronitis, non-alcoholic fatty liver disease, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vulgarisvularis), pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonia, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, portal vein inflammation, radiation-induced injury, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, rectal spasm, congestion dermatitis, stenosis, stomatitis, stroke, surgical complications, synovitis, tendonitis, tendinosis, synovitis, thrombophlebitis, thyroiditis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, ulcer, urethritis, ursitis, uveitis, vaginitis, vasculitis, and vulvitis.

[0114] General categories of diseases, disorders and trauma that may result in or otherwise cause acute and / or chronic inflammation include, but are not limited to, genetic diseases, abnormal proliferation, direct tissue injury, autoimmune diseases, infectious diseases, vascular diseases / complications (e.g., ischemia / reperfusion injury), iatrogenic causes (e.g., adverse drug effects, radiation injury, etc.), and allergic conditions.

[0115] In one embodiment, acute and / or chronic inflammation includes tissue inflammation. Generally, tissue inflammation is acute and / or chronic inflammation limited to a specific tissue or organ. Thus, for example, tissue inflammation can include skin inflammation, muscle inflammation, tendon inflammation, ligament inflammation, bone inflammation, cartilage / joint inflammation, lung inflammation, heart inflammation, liver inflammation, gallbladder inflammation, pancreas inflammation, kidney inflammation, bladder inflammation, gum inflammation, esophageal inflammation, stomach inflammation, intestinal inflammation, anal inflammation, rectal inflammation, vascular inflammation, vaginal inflammation, uterine inflammation, testicular inflammation, penile inflammation, vulvar inflammation, neuronal inflammation, oral inflammation, eye inflammation, ear inflammation, brain inflammation, ventricular / meningeal inflammation, and / or inflammation involving central or peripheral nervous system cells / elements. do.

[0116] In another embodiment, acute and / or chronic inflammation includes systemic inflammation. Although the processes involved are similar, if not identical, to tissue inflammation, systemic inflammation is not limited to specific tissues but rather involves multiple body sites, including epithelium, endothelium, neural tissue, serosal surfaces, and organ systems. When caused by an infectious disease, the term sepsis can be used with bacteremia specifically referring to bacterial sepsis and viremia specifically referring to viral sepsis. Vasodilation and organ dysfunction are serious problems associated with widespread infection, which can lead to septic shock and death.

[0117] In another embodiment, the acute and / or chronic inflammation is induced by arthritis. Arthritis includes a group of conditions involving damage to the body's joints due to inflammation of the synovial membrane, including, for example, osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthropathies such as ankylosing spondylitis, reactive arthritis (Reiter's syndrome), psoriatic arthritis, enteropathic arthritis associated with inflammatory bowel disease, Whipple's disease and Behçet's disease, septic arthritis, gout (also commonly referred to as gouty arthritis, crystalline synovitis, and metabolic arthritis), pseudogout (calcium pyrophosphate deposition disease), and Still's disease. Arthritis can affect a single joint (monoarthritis), two to four joints (oligoarthritis), or five or more joints (polyarthritis), and can be either an autoimmune disease or a non-autoimmune disease.

[0118] In another embodiment, acute and / or chronic inflammation is induced by autoimmune disorders. Autoimmune diseases can be broadly divided into systemic and organ-specific autoimmune disorders according to the main clinicopathological features of each disease. Systemic autoimmune diseases include, for example, systemic lupus erythematosus (SLE), Sjögren's syndrome, scleroderma, rheumatoid arthritis, and polymyositis. Local autoimmune diseases can be endocrine (such as type 1 diabetes mellitus, Hashimoto's disease, and Addison's disease), dermatological (pemphigus vulgaris), hematological (autoimmune hemolytic anemia), neurological (multiple sclerosis), or can involve virtually any localized mass of body tissue. Types of autoimmune disorders include acute disseminated encephalomyelitis (ADEM), Addison's disease, allergies or hypersensitivity disorders, amyotrophic lateral sclerosis (ALS), antiphospholipid syndrome (APS), arthritis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune pancreatitis, bullous pemphigus, celiac disease, Chagas disease, chronic obstructive pulmonary disease (COPD) (including acute exacerbations), type 1 diabetes mellitus (IDDM), endometriosis, fibromyalgia, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, hidradenitis suppurativa, and idiopathic thrombocytopenic purpura. The acute and / or chronic inflammation may be caused by, but is not limited to, plaque disease, inflammatory bowel disease (IBD), interstitial cystitis, lupus (including discoid lupus erythematosus, drug-induced lupus erythematosus, lupus nephritis, neonatal lupus, subacute cutaneous lupus erythematosus, and systemic lupus erythematosus), localized scleroderma, multiple sclerosis (MS), myasthenia gravis, myopathy, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anemia, primary biliary cirrhosis, relapsing disseminated encephalomyelitis (multiphasic disseminated encephalomyelitis), rheumatic fever, schizophrenia, scleroderma, Sjogren's syndrome, synovitis, vasculitis, and vitiligo. In a specific embodiment, the acute and / or chronic inflammation is caused by, or is otherwise caused by, diabetes in the subject. In another specific embodiment, the acute and / or chronic inflammation is caused by, or is otherwise caused by, multiple sclerosis in the subject.

[0119] In another embodiment, acute and / or chronic inflammation is induced by myopathy. Generally, myopathy occurs when the immune system inappropriately attacks muscle components, resulting in muscle inflammation. Myopathy includes, for example, inflammatory myopathy and autoimmune myopathy. Myopathy includes, for example, dermatomyositis, inclusion body myositis, and polymyositis.

[0120] In another embodiment, acute and / or chronic inflammation is induced by vasculitis. Vasculitis is a group of disorders characterized by inflammation of blood vessel walls, including lymphatic vessels and blood vessels such as veins (phlebitis), arteries (arteritis), and capillaries, due to leukocyte migration and resulting damage. Inflammation can affect blood vessels of any size and anywhere in the body. It can affect both arteries and / or veins. Inflammation can be focal, meaning that a single location in a blood vessel is affected, or it can be widespread, with areas of inflammation scattered throughout a specific organ or tissue, or it can affect two or more organ systems in the body. Vasculitides include, but are not limited to, Buerger's disease (thromboangiitis obliterans), cerebral vasculitis (central nervous system vasculitis), ANCA-associated vasculitis, Churg-Strauss arteritis, cryoglobulinemia, essential cryoglobulinemic vasculitis, giant cell (temporal) arteritis, golfer's vasculitis, Henoch-Schonlein purpura, hypersensitivity vasculitis (allergic vasculitis), Kawasaki disease, microscopic polyarteritis / polyangiitis, polyarteritis nodosa, polymyalgia rheumatica (PMR), rheumatoid vasculitis, Takayasu's arteritis, Wegener's granulomatosis, and vasculitis associated with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), relapsing polychondritis, connective tissue disorders such as Behcet's disease, or other connective tissue disorders, or viral infections.

[0121] In another embodiment, the acute and / or chronic inflammation is caused by a skin disorder.Such skin disorders include acne including acne vulgaris, bullous pemphigoid, dermatitis including atopic dermatitis and acute and / or chronic actinic dermatitis, eczematous atopic eczema, contact eczema, dry eczema, seborrheic dermatitis, dyshidrosis, nummular eczema, venous eczema, dermatitis, dermatitis herpetiformis, neurodermatitis, and autoeczematization, and stasis dermatitis, diabetic skin complications, hidradenitis suppurativa, lichen planus, psoriasis including plaque psoriasis, nail psoriasis, guttate psoriasis, scalp psoriasis, psoriasis invertis, pustular psoriasis, erythrodermic psoriasis, and psoriatic arthritis, scleroderma including rosacea and localized scleroderma, and ulcers.

[0122] In another embodiment, the acute and / or chronic inflammation is induced by a gastrointestinal disorder, such as irritable bowel disease (IBD), inflammatory bowel disease, including ulcerative proctitis such as Crohn's disease and ulcerative colitis, left-sided colitis, pancolitis, and fulminant colitis.

[0123] In another embodiment, acute and / or chronic inflammation is caused by cardiovascular disease.When LDL cholesterol is embedded in arterial wall, it can provoke immune response.Acute and / or chronic inflammation can eventually damage arteries, which can cause arteries to rupture.Generally, cardiovascular disease is any of many specific diseases that affect the heart itself and / or vascular system, especially the veins and arteries that lead to and from the heart.For example, there are more than 60 types of cardiovascular disorders, including hypertension, endocarditis, myocarditis, heart valve dysfunction, congestive heart failure, myocardial infarction, diabetic heart condition, vascular inflammation such as arteritis, phlebitis, vasculitis; arterial occlusive disease such as arteriosclerosis and stenosis, inflammatory cardiac hypertrophy, peripheral arterial disease; aneurysm; embolism; dissection; pseudoaneurysm; vascular malformation; vascular nevus; thrombosis; thrombophlebitis; varicose vein; and stroke. Symptoms of cardiovascular disorders affecting the heart include, but are not limited to, chest pain or chest discomfort (angina), pain in one or both arms, left shoulder, neck, jaw, or back, shortness of breath, dizziness, rapid heartbeat, nausea, abnormal heartbeat, and fatigue.Symptoms of cardiovascular disorders affecting the brain include, but are not limited to, sudden numbness or weakness in the face, arms, or legs, especially on one side of the body, sudden confusion or difficulty in understanding speech or conversation, sudden vision problems in one or both eyes, sudden dizziness, difficulty walking or loss of balance or coordination, and sudden severe headache of unknown cause.Symptoms of cardiovascular disorders affecting the legs, pelvis, and / or arms include, but are not limited to, claudication, which is muscle pain, pain, or spasms, and cold or numb feeling in the feet or toes, especially at night.

[0124] In another embodiment, acute and / or chronic inflammation is induced by cancer. Generally, inflammation organizes the microenvironment around tumors, promoting their proliferation, survival, and migration. For example, fibrinous inflammation results from a significant increase in vascular permeability, allowing fibrin to pass through blood vessels. In the presence of an appropriate procoagulant stimulus, such as cancer cells, fibrinous exudates are deposited. Deposition is commonly found in serosal cavities, where the fibrinous exudates can transform into scars between the serosa, limiting the function of the serosa. In another example, the cancer is an inflammatory cancer, such as an NF-κB-driven inflammatory cancer.

[0125] In another embodiment, the acute and / or chronic inflammation is pharmacologically induced inflammation. It is known that certain drugs or exogenous compounds, including deficiencies of important vitamins and minerals, can cause inflammation. For example, vitamin A deficiency causes an increased inflammatory response, vitamin C deficiency causes connective tissue disease, and vitamin D deficiency causes osteoporosis. Certain pharmacological agents can induce inflammatory complications, such as drug-induced hepatitis. Certain illegal drugs, such as cocaine and ecstasy, can have some adverse effects by activating transcription factors (e.g., NF-κB) closely related to inflammation. Radiation therapy can induce pulmonary toxicity, burns, myocarditis, mucositis, and other tissue damage, depending on the site of exposure and administration.

[0126] In another embodiment, acute and / or chronic inflammation is induced by an infectious disease. If an infectious organism can spread to other parts of the body, it can escape to the borders of adjacent tissues via the circulatory system or lymphatic system. If the organism is not involved in the effects of acute inflammation, it can access the lymphatic system via nearby lymphatic vessels. Infection of the lymphatic vessels is known as lymphangitis, and infection of the lymph nodes is known as lymphadenitis. Pathogens can access the bloodstream through lymphatic drainage into the circulatory system. Infectious diseases include, but are not limited to, bacterial cystitis, bacterial encephalitis, pandemic influenza, viral encephalitis, and viral hepatitis (A, B, and C).

[0127] In another embodiment, the acute and / or chronic inflammation is induced by tissue or organ injury, including but not limited to, a burn, laceration, wound, puncture, or trauma.

[0128] In another embodiment, acute and / or chronic inflammation is induced by transplant rejection. Transplant rejection occurs when a transplanted organ or tissue is not accepted by the transplant recipient's body because the recipient's immune system attacks the transplanted organ or tissue. Adaptive immune responses, transplant rejection, are mediated by both T cell-mediated and humoral immune (antibody) mechanisms. Transplant rejection can be classified as hyperacute rejection, acute rejection, or chronic rejection. Acute and / or chronic rejection of a transplanted organ or tissue is due to a poorly understood acute and / or chronic inflammatory immune response against the transplanted tissue. Transplant rejection also includes graft-versus-host disease (GVHD), either acute or chronic. GVHD is a common complication of allogeneic bone marrow transplantation, in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and launch an immunological attack. It can also occur in blood transfusions under certain circumstances. GVHD is divided into acute and chronic forms. Acute and chronic GVHD appear to involve different immune cell subsets, different cytokine profiles, somewhat different host targets, and respond differently to treatment. In another embodiment, the acute and / or chronic inflammation is induced by a Th1-mediated inflammatory disease.

[0129] A properly functioning immune system should produce a balanced pro-inflammatory Th1 response and an anti-inflammatory Th2 response suitable for immune induction. Generally speaking, once a pro-inflammatory Th1 response is initiated, the body counteracts it with an anti-inflammatory response evoked by a Th2 response. This counter-response includes the release of Th2-type cytokines, such as IL-4, IL-5, and IL-13, which are associated with the promotion of IgE and eosinophilic responses in atopy, as well as IL-10, which has an anti-inflammatory response. Th1-mediated inflammatory diseases involve excessive pro-inflammatory responses generated by Th1 cells, resulting in acute and / or chronic inflammation. Th1-mediated diseases can be virally, bacterially, or chemically (e.g., environmentally) induced. For example, viruses that cause Th1-mediated diseases can cause chronic or acute infections, leading to respiratory disorders or influenza.

[0130] In another embodiment, acute and / or chronic inflammation includes acute and / or chronic neurogenic inflammation. Acute and / or chronic neurogenic inflammation refers to an inflammatory response initiated and / or maintained by the release of inflammatory molecules such as SP or CGRP from peripheral sensory nerve endings (i.e., an efferent function, as opposed to the normal afferent signaling in these nerves to the spinal cord). Acute and / or chronic neurogenic inflammation includes both primary and secondary neurogenic inflammation. Primary neurogenic inflammation refers to tissue inflammation (inflammatory symptoms) initiated by or resulting from the release of substances from primary sensory nerve endings (e.g., C and A-delta fibers). Secondary neurogenic inflammation refers to tissue inflammation initiated by inflammatory mediators of non-neuronal origin (e.g., extravasation from vascular beds or tissues derived from the interstitium, such as mast cells or immune cells), such as peptides or cytokines, which stimulate sensory nerve endings and cause the release of inflammatory mediators from nerves. The net effect of both forms (primary and secondary) of acute and / or chronic neurogenic inflammation can be an inflammatory state maintained by sensitization of peripheral sensory nerve fibers. The physiological consequences of the resulting acute and / or chronic neurogenic inflammation depend on the tissue in question, resulting in, for example, cutaneous pain (allodynia, hyperalgesia), joint pain and / or arthritis, visceral pain and dysfunction, pulmonary dysfunction (asthma, COPD), and bladder dysfunction (pain, overactive bladder). conclusion

[0131] Here, we report functional and biochemical evaluation of two distinct approaches using the alpha(1,3)-fucosyltransferase FUT6 for the transient increase of cell surface E-selectin ligands and their effect on MSC homing to bone using multiple primary human MSC lines. This study represents the first direct comparison between intracellular and extracellular fucosylation using the same enzyme in a clinically relevant experimental model. Compared to untreated MSCs, both intracellular and extracellular fucosylation significantly increased cell surface E-selectin ligands and improved osteotropism in all primary MSC lines tested, demonstrating that these approaches are consistent and valid across multiple MSC donors. Notably, 24 hours after transplantation, the levels of overall osteotropism and extravasation were significantly higher with intracellular fucosylation than with extracellular fucosylation. This finding likely reflects the more persistent expression and increased diversity of cell surface E-selectin ligands on intracellularly fucosylated versus extracellularly fucosylated MSCs. Collectively, these results demonstrate that this simple, non-persistent strategy to enforce fucosylation can be used to enhance the homing of transplanted MSCs. Cited literature [ka] [ka] [ka] [ka] [ka]

[0132] All documents cited in this application are incorporated herein as if recited in full herein.

[0133] Although illustrative embodiments of the present invention have been described herein, it should be understood that the invention is not limited to the described embodiments and that various other changes or modifications can be made by those skilled in the art without departing from the scope or spirit of the invention. In certain embodiments, for example, the following items are provided: (Item 1) 1. A method for enforcing expression of E-selectin and / or L-selectin ligands on the surface of a cell, comprising: providing said cell with a nucleic acid encoding a glycosyltransferase; culturing the cells under conditions sufficient to express the glycosyltransferase; wherein the expressed glycosyltransferase modifies terminal sialylated lactosamines present on glycoproteins of the cell to force expression of the E-selectin and / or L-selectin ligand. (Item 2) 2. The method of claim 1, wherein the glycosyltransferase is an alpha 1,3-fucosyltransferase. (Item 3) 3. The method of claim 2, wherein the alpha 1,3-fucosyltransferase is alpha 1,3-fucosyltransferase FTIII, FTIV, FTV, FTVI, FTVII, or a combination thereof. (Item 4) 3. The method of claim 2, wherein the glycosyltransferase modifies the terminal sialylated lactosamine intracellularly. (Item 5) 1. A method for enabling and / or increasing cell binding to E-selectin and / or L-selectin, comprising: providing said cell with a nucleic acid encoding an alpha 1,3-fucosyltransferase; culturing the cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by the cells; wherein the alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to generate E-selectin and / or L-selectin ligands, thereby enabling and / or increasing binding of the cells to E-selectin and / or L-selectin. (Item 6) 6. The method of claim 5, wherein the cell is a mammalian cell. (Item 7) 7. The method of claim 6, wherein the mammalian cells are human cells. (Item 8) 6. The method of claim 5, wherein the cells are stem cells. (Item 9) 9. The method of claim 8, wherein the stem cells are selected from the group consisting of embryonic stem cells, adult stem cells, hematopoietic stem cells, and induced pluripotent stem cells (iPSCs). (Item 10) Item 10. The method of item 9, wherein the adult stem cells are mesenchymal stem cells. (Item 11) 6. The method of claim 5, wherein the nucleic acid is provided to the cell by transfection. (Item 12) 6. The method of claim 5, wherein the nucleic acid is provided to the cell by transduction. (Item 13) Item 14. The method of item 5, wherein the nucleic acid is selected from the group consisting of DNA, RNA, a DNA / RNA hybrid, cDNA, mRNA, modified forms thereof, and combinations thereof. 14. The method of claim 13, wherein the nucleic acid is a modified RNA. (Item 15) 15. The method of claim 14, wherein the modified RNA is modRNA. (Item 16) 6. The method of claim 5, wherein the alpha 1,3-fucosyltransferase is a human alpha 1,3-fucosyltransferase. (Item 17) 6. The method of claim 5, wherein the alpha 1,3-fucosyltransferase is human FTVI. (Item 18) 6. The method of claim 5, wherein the alpha 1,3-fucosyltransferase fucosylates a glycoprotein selected from the group consisting of PSGL-1, CD43, CD44, and combinations thereof. (Item 19) 1. A method for increasing homing and / or extravasation in a population of cells transplanted into a subject, comprising: providing to said population of cells a nucleic acid encoding an alpha 1,3-fucosyltransferase; culturing the population of cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the alpha 1,3-fucosyltransferase fucosylates glycan chains present on glycoproteins to produce modified cells having enforced E-selectin and / or L-selectin ligand expression; transplanting the population of cells into the subject; wherein said modified cells with enforced E-selectin and / or L-selectin ligand expression exhibit increased homing and / or extravasation to therapeutically useful sites. (Item 20) 20. The method of claim 19, wherein the population of cells is a population of mammalian cells. (Item 21) 21. The method of claim 20, wherein the population of cells is a population of human cells. (Item 22) 20. The method of item 19, wherein the population of mammalian cells is a population of stem cells. (Item 23) 23. The method of claim 22, wherein the population of stem cells is selected from the group consisting of embryonic stem cells, adult stem cells, hematopoietic stem cells, and induced pluripotent stem cells (iPSCs). (Item 24) 24. The method of claim 23, wherein the adult stem cells are mesenchymal stem cells. (Item 25) 20. The method of claim 19, wherein the nucleic acid is provided to the population of cells by transfection. (Item 26) 27. The method of claim 19, wherein the nucleic acid is provided to the population of cells by transduction. 20. The method of claim 19, wherein the nucleic acid is selected from the group consisting of DNA, RNA, a DNA / RNA hybrid, cDNA, mRNA, modified forms thereof, and combinations thereof. (Item 28) 20. The method of claim 19, wherein the nucleic acid is a modified RNA. (Item 29) 29. The method of claim 28, wherein the modified RNA is modRNA. (Item 30) 20. The method of claim 19, wherein the alpha 1,3-fucosyltransferase is a human alpha 1,3-fucosyltransferase. (Item 31) 20. The method of claim 19, wherein the alpha 1,3-fucosyltransferase is human FTVI. (Item 32) 20. The method of claim 19, wherein the alpha 1,3-fucosyltransferase fucosylates a glycoprotein selected from the group consisting of PSGL-1, CD43, CD44, and combinations thereof. (Item 33) 20. The method of claim 19, wherein the implanting step is performed intravenously. (Item 34) 20. The method of claim 19, wherein the implanting step occurs near a desired extravasation site. (Item 35) 1. A method of producing modified cells for transplantation into a subject in need thereof, comprising: Obtaining a population of cells to be modified; providing to said population of cells a nucleic acid encoding an alpha 1,3-fucosyltransferase; culturing the population of cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population; wherein the alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to generate E-selectin and / or L-selectin ligands. (Item 36) 36. The method of claim 35, wherein the population of cells is a population of mammalian cells. (Item 37) 37. The method of claim 36, wherein the population of mammalian cells is a population of human cells. (Item 38) 36. The method of claim 35, wherein the population of cells is a population of stem cells. (Item 39) 39. The method of claim 38, wherein the population of stem cells is selected from the group consisting of embryonic stem cells, adult stem cells, hematopoietic stem cells, and induced pluripotent stem cells (iPSCs). (Item 40) 40. The method of claim 39, wherein the adult stem cells are mesenchymal stem cells. (Item 41) 36. The method of claim 35, wherein the nucleic acid is provided to the population of cells by transfection. (Item 42) 43. The method of claim 35, wherein the nucleic acid is provided to the population of cells by transduction. 36. The method of claim 35, wherein the alpha 1,3-fucosyltransferase is a human alpha 1,3-fucosyltransferase. (Item 44) 36. The method of claim 35, wherein the alpha 1,3-fucosyltransferase is human FTVI. (Item 45) 36. The method of claim 35, wherein the alpha 1,3-fucosyltransferase fucoylate a glycoprotein selected from the group consisting of PSGL-1, CD43, CD44, and combinations thereof. (Item 46) 1. A method of producing modified stem cells for transplantation into a subject, comprising: Obtaining a population of stem cells to be modified; providing said population of stem cells with cDNA or modified RNA encoding an alpha 1,3-fucosyltransferase; and culturing the population of stem cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the expressed alpha 1,3-fucosyltransferase fucosylates CD44 present on or within the one or more modified cells. (Item 47) 47. The method of claim 46, wherein the alpha 1,3-fucosyltransferase is human FTVI. (Item 48) Item 47. The method of item 46, wherein the stem cells are human stem cells. (Item 49) 49. The method of claim 48, wherein the human stem cells are selected from the group consisting of embryonic stem cells, adult stem cells, hematopoietic stem cells, and induced pluripotent stem cells (iPSCs). (Item 50) Item 49. The method of item 49, wherein the adult stem cells are mesenchymal stem cells. (Item 51) 47. The method of claim 46, wherein the cDNA or modified RNA is provided by transduction. (Item 52) 52. The method of claim 51, wherein the modified RNA is modRNA. (Item 53) 53. The method of any one of items 1 to 52, further comprising a step of performing extracellular fucosylation of CD44 on the surface of the stem cells. (Item 54) 1. A method of treating or ameliorating the effects of a condition, disease, or injury in a subject in need thereof, comprising: Obtaining a population of cells produced by the method according to any one of items 35 to 53; transplanting an effective amount of the population of cells into the subject; wherein said transplanted cells extravasate to sites expressing E-selectin and / or L-selectin, thereby treating or ameliorating the effects of said condition, disease or injury in said subject. (Item 55) 55. The method of claim 54, wherein the disease is selected from the group consisting of an inflammatory disorder, an autoimmune disease, a degenerative disease, a cardiovascular disease, an ischemic disease, a cancer, a genetic disease, a metabolic disorder, and an idiopathic disorder. (Item 56) 55. The method of claim 54, wherein the injury is selected from the group consisting of a physical injury, a drug side effect, a toxic injury, and an iatrogenic condition. (Item 57) 55. The method of claim 54, wherein the subject is a mammal. (Item 58) 58. The method of claim 57, wherein the mammal is selected from the group consisting of humans, primates, agricultural animals, and domestic animals. (Item 59) 59. The method of claim 58, wherein the mammal is a human. (Item 60) 55. The method of item 54, wherein the transplantation occurs intravenously. (Item 61) 55. The method of claim 54, wherein the implantation occurs near the desired extravasation site. (Item 62) 62. The method of claim 61, wherein the desired extravasation site is bone marrow. (Item 63) 62. The method of claim 61, wherein the desired extravasation site is a site of injury or inflammation. (Item 64) 54. A pharmaceutical composition comprising a population of cells produced by the method according to any one of items 35 to 53 and a pharmaceutically acceptable carrier. (Item 65) 65. A kit for treating or ameliorating the effects of a condition, disease or injury in a subject in need thereof, comprising the composition of item 64 packaged together with instructions for its use. (Item 66) 1. A method for inducing and / or enhancing homing of a population of cells to a therapeutic target in a subject in need thereof, comprising: (a) providing to said population of cells a nucleic acid encoding a polypeptide that forces the transient expression of a ligand that binds to a receptor at said therapeutic target; (b) expressing the polypeptide in the population of cells; wherein upon expression of said polypeptide, homing of one or more cells in said population to a therapeutic target is induced and / or enhanced. (Item 67) 67. The method of claim 66, wherein the population of cells is selected from the group consisting of stem cells, tissue progenitor cells, antigen-specific T cells, T regulatory cells, antigen-pulsed dendritic cells, NK cells, NKT cells, and leukocytes. (Item 68) 68. The method of claim 67, wherein the population of cells is T-lymphocytes. (Item 69) 68. The method of claim 67, wherein the population of cells is chimeric antigen receptor T cells. (Item 70) 67. The method of claim 66, wherein the population of cells has been expanded in culture prior to step (a). (Item 71) Item 67. The method of item 66, wherein the therapeutic target is a tumor.

Claims

1. 1. A method of enforcing expression of E-selectin and / or L-selectin ligands on the surface of one or more of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or induced pluripotent stem cells (iPSCs) to increase extravasation to sites expressing E-selectin and / or L-selectin in a subject, comprising: providing said embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs with a nucleic acid encoding an alpha 1,3-fucosyltransferase; Culturing said embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs under conditions sufficient to express said alpha 1,3-fucosyltransferase. wherein the expressed alpha 1,3-fucosyltransferase modifies terminal sialylated lactosamines present on glycoproteins of the cells to force expression of the E-selectin and / or L-selectin ligands and increase extravasation of the embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs to sites expressing E-selectin and / or L-selectin.

2. 2. The method of claim 1, wherein the alpha 1,3-fucosyltransferase is an alpha 1,3-fucosyltransferase FTIII, FTIV, FTV, FTVI, FTVII, and combinations thereof.

3. The method of claim 2, wherein the alpha 1,3-fucosyltransferase modifies a terminal sialylated lactosamine intracellularly.

4. 1. A method of enabling and / or increasing binding of one or more of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or induced pluripotent stem cells (iPSCs) to E-selectin and / or L-selectin and increasing extravasation of said embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs to sites expressing E-selectin and / or L-selectin, comprising: providing said embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs with a nucleic acid encoding an alpha 1,3-fucosyltransferase; Culturing the embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs under conditions sufficient for expression of the alpha 1,3-fucosyltransferase. wherein said alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to generate E-selectin and / or L-selectin ligands, thereby enabling and / or increasing binding of said embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs to E-selectin and / or L-selectin and increasing extravasation of said embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs.

5. The method of claim 4, wherein the embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs are mammalian embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs.

6. The method of claim 5, wherein the mammalian embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs are human embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs.

7. The method of claim 4 , wherein the nucleic acid is provided to the cell by transfection.

8. The method of claim 4 , wherein the nucleic acid is provided to the cell by transduction.

9. The method of claim 4, wherein the nucleic acid is selected from the group consisting of DNA, RNA, DNA / RNA hybrids, cDNA, mRNA, modified forms thereof, and combinations thereof.

10. The method of claim 9, wherein the nucleic acid is a modified RNA.

11. The method of claim 10, wherein the modified RNA is a modRNA.

12. 5. The method of claim 4, wherein the alpha 1,3-fucosyltransferase is a human alpha 1,3-fucosyltransferase.

13. The method of claim 4, wherein the alpha 1,3-fucosyltransferase is human FTVI.

14. The method of claim 4, wherein the alpha 1,3-fucosyltransferase fucosylates a glycoprotein selected from the group consisting of PSGL-1, CD43, CD44, and combinations thereof.

15. 1. A composition comprising a population of modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or induced pluripotent stem cells (iPSCs) with enforced E-selectin and / or L-selectin ligand expression to increase extravasation to sites expressing E-selectin and / or L-selectin in a subject, comprising: The modified population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or induced pluripotent stem cells (iPSCs) comprises: providing a population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs with a nucleic acid encoding an alpha 1,3-fucosyltransferase to generate a population of transformed cells; culturing the population of transformed cells under conditions sufficient for expression of the alpha 1,3-fucosyltransferase by one or more modified cells within the population, wherein the alpha 1,3-fucosyltransferase fucosylates glycan chains present on glycoproteins to produce modified transformed cells having enforced E-selectin and / or L-selectin ligand expression. The composition is characterized in that it is produced by a method comprising: The modified transformed cell population is transplanted into the subject, wherein the transplanted cells with enforced E-selectin and / or L-selectin ligand expression exhibit increased extravasation to sites expressing E-selectin and / or L-selectin.

16. The composition of claim 15 , wherein the population of cells is a population of mammalian cells.

17. The composition of claim 16 , wherein the population of cells is a population of human cells.

18. The composition of claim 15 , wherein the nucleic acid is provided to the population of cells by transfection.

19. The composition of claim 15 , wherein the nucleic acid is provided to the population of cells by transduction.

20. 16. The composition of claim 15, wherein the nucleic acid is selected from the group consisting of DNA, RNA, DNA / RNA hybrids, cDNA, mRNA, modified forms thereof, and combinations thereof.

21. The composition of claim 15 , wherein the nucleic acid is a modified RNA.

22. 22. The composition of claim 21 , wherein the modified RNA is a modRNA.

23. 16. The composition of claim 15, wherein the alpha 1,3-fucosyltransferase is a human alpha 1,3-fucosyltransferase.

24. The composition of claim 15, wherein the alpha 1,3-fucosyltransferase is human FTVI.

25. 16. The composition of claim 15, wherein the alpha 1,3-fucosyltransferase fucosylates a glycoprotein selected from the group consisting of PSGL-1, CD43, CD44, and combinations thereof.

26. The composition of claim 15, wherein the population of modified transformed cells is implanted intravenously.

27. The composition of claim 15, wherein the population of modified transformed cells is transplanted near a desired site of extravasation.

28. 1. A method of generating modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or induced pluripotent stem cells (iPSCs) with enforced E-selectin and / or L-selectin ligand expression for transplantation into a subject in need thereof, comprising: Obtaining a population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs to be modified; providing said population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs with a nucleic acid encoding an alpha 1,3-fucosyltransferase; culturing said population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs under conditions sufficient for expression of said alpha 1,3-fucosyltransferase in said population to generate a population of modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs; wherein the alpha 1,3-fucosyltransferase modifies glycan chains present on glycoproteins to generate E-selectin and / or L-selectin ligands, and the modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs have increased extravasation at sites expressing E-selectin and / or L-selectin in the subject.

29. 29. The method of claim 28, wherein the population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs is a population of mammalian embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs.

30. 30. The method of claim 29, wherein the population of mammalian embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs is a population of human embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs.

31. 29. The method of claim 28, wherein the nucleic acid is provided to the population of cells by transfection. The method according to

32. 30. The method of claim 28, wherein the nucleic acid is provided to the population of cells by transduction.

33. 29. The method of claim 28, wherein the alpha 1,3-fucosyltransferase is a human alpha 1,3-fucosyltransferase.

34. 29. The method of claim 28, wherein the alpha 1,3-fucosyltransferase is human FTVI.

35. 29. The method of claim 28, wherein the alpha 1,3-fucosyltransferase fucosylates a glycoprotein selected from the group consisting of PSGL-1, CD43, CD44, and combinations thereof.

36. 1. A method of generating modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or induced pluripotent stem cells (iPSCs) for transplantation into a subject, comprising: Obtaining a population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs to be modified; providing said population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs with a cDNA or modified RNA encoding an alpha 1,3-fucosyltransferase; culturing said population of embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs under conditions sufficient for expression of said alpha 1,3-fucosyltransferase by one or more embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs within said population to generate a population of modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs; wherein the expressed alpha 1,3-fucosyltransferase fucosylates CD44 present on or within the one or more modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs, and wherein the modified embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs have increased extravasation at sites expressing E-selectin and / or L-selectin in the subject.

37. 37. The method of claim 36, wherein the alpha 1,3-fucosyltransferase is human FTVI.

38. 37. The method of claim 36, wherein the embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs are human embryonic stem cells, adult stem cells, hematopoietic stem cells, and / or iPSCs.

39. 37. The method of claim 36, wherein the cDNA or modified RNA is provided by transduction.

40. 40. The method of claim 39, wherein the modified RNA is a modRNA.

41. The method of any one of claims 1 to 14 and 28 to 40, further comprising the step of performing extracellular fucosylation of CD44 on the surface of said stem cells.

42. 41. A pharmaceutical composition comprising a population of cells produced by the method of any one of claims 28 to 40 for treating or ameliorating the effects of a condition, disease or injury in a subject in need thereof, characterized in that said population of cells is obtained and transplanted into said subject, wherein said transplanted cells extravasate to sites expressing E-selectin and / or L-selectin, thereby treating or ameliorating the effects of said condition, disease or injury in said subject, wherein said disease is selected from the group consisting of inflammatory disorders, autoimmune diseases, degenerative diseases, cardiovascular diseases, ischemic diseases, cancer, genetic diseases, metabolic disorders, and idiopathic disorders, and said injury is selected from the group consisting of physical injury, adverse drug reactions, toxic injury, and iatrogenic conditions.

43. 43. The pharmaceutical composition of claim 42, wherein the subject is a mammal.

44. 44. The pharmaceutical composition of claim 43, wherein the mammal is selected from the group consisting of humans, primates, agricultural animals, and domestic animals.

45. 45. The pharmaceutical composition of claim 44, wherein the mammal is a human.

46. 43. The pharmaceutical composition of claim 42, wherein the population of cells is implanted intravenously.

47. 43. The pharmaceutical composition of claim 42, wherein the population of cells is implanted near a desired site of extravasation.

48. 48. The pharmaceutical composition of claim 47, wherein the desired extravasation site is the bone marrow.

49. 48. The pharmaceutical composition of claim 47, wherein the desired site of extravasation is a site of injury or inflammation.

50. 48. A kit for treating or ameliorating the effects of a condition, disease or injury in a subject in need thereof, comprising the pharmaceutical composition of claim 47 packaged together with instructions for its use.

51. 42. A pharmaceutical composition comprising the population of cells produced by the method of claim 41 for treating or ameliorating the effects of a condition, disease or injury in a subject in need thereof, wherein said population of cells is transplanted into said subject and said transplanted cells extravasate to sites expressing E-selectin and / or L-selectin, thereby treating or ameliorating the effects of said condition, disease or injury in said subject, wherein said disease is selected from the group consisting of inflammatory disorders, autoimmune diseases, degenerative diseases, cardiovascular diseases, ischemic diseases, cancer, genetic diseases, metabolic disorders, and idiopathic disorders, and said injury is selected from the group consisting of physical injury, adverse drug reactions, toxic injury, and iatrogenic conditions.